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ABSTRACT

Hypertension and HIV in an Urban Slum Setting, Port-au-Prince, Haiti
by
Olga Tymejczyk

Advisor: Denis Nash, PhD MPH
BACKGROUND: Rapidly growing urban slum settings increasingly face co-occurring communicable and
non-communicable health crises, against the backdrop of extreme poverty, and social and
environmental vulnerability. In Haiti, sparse data suggest a growing burden of hypertension and
cardiovascular disease (CVD), along with substantial prevalence of HIV, increasingly recognized as a
major CVD risk factor. As life-saving antiretroviral treatment (ART) is extended to more people living
with HIV (PLWH), their risk of CVD increases with longer life expectancy and possibly cumulative ART
exposure. Pregnant HIV-positive women may face additional cardiovascular vulnerability, due to the risk
of gestational hypertension and pre-eclampsia. Integration of hypertension and broader noncommunicable disease (NCD) services is increasingly recommended and piloted in vertical HIV programs,
though often complicated by challenges with facility preparedness. The goal of this dissertation was to
examine the burden and patterns of hypertension, as well as related healthcare needs, among slum
community residents and PLWH receiving standard HIV care services at a clinic serving large slum
communities in Port-au-Prince, Haiti.
METHODS: This work utilizes cross-sectional primary data from a population-representative community
survey (aim 1) and longitudinal secondary data from the electronic medical records of a local HIV clinic
(aims 2 and 3), altogether spanning the period from 2007 to 2017. In aim 1, data from a multistage
randomized survey were used to characterize the prevalence, correlates, and care continuum of
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hypertension among residents of four slum communities in Port-au-Prince. In aim 2, hypertension
prevalence, incidence, and patterns following onset were examined among newly diagnosed with HIV
patients initiating ART at a local HIV clinic. In aim 3, trends in the prevalence and incidence of gestational
and chronic hypertension, and longitudinal blood pressure trajectories, were assessed among HIVpositive pregnant women with and without prior ART exposure in a prevention-of-maternal-to-childtransmission (PMTCT) program.
RESULTS: In aim 1, among adult slum community residents with a median age of 28 years, 20% screened
positive for hypertension using a single-day definition, with overweight and obesity being the most
common risk factor (21% among men and 49% among women), and a low prevalence of smoking (12%
among men and 4% among women). Individual’s odds of hypertension rose with hypertension
prevalence in immediate surroundings. Four out of ten persons with hypertension on the day of the
survey had been previously told by a clinician that they had the condition, but fewer than one in ten
reported receiving treatment.
In aims 2 and 3, the gold standard two-day definition of hypertension was applied. In aim 2, among
newly diagnosed with HIV persons with a median age of 37 years, and relatively low prevalence of
overweight and obesity (16%), 12% of patients had hypertension at enrollment and among those initially
hypertension-free, 19% developed hypertension within the first 18 months of HIV care and treatment.
While patients with lowest enrollment CD4 counts (≤ 100 cells/µl) at enrollment had lower hypertension
prevalence (8%), they were at a greater risk of hypertension incidence than patients with higher CD4
counts (15 versus 10 per 100 person-years of follow-up). Following onset, 44% of patients had
hypertension on half or more of the subsequent measurements over a median of 24 months of followup. Patients with initial stage 1 hypertension and younger patients were less likely to maintain
hypertensive status during follow-up.
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In aim 3, threefold increases in the rates of chronic and gestational hypertension were observed over
time among pregnant women (median age of 29 years) enrolled in a PMTCT program between 2007 and
2016. In the most recent period, 2013-2016, 4% of pregnancies were affected by chronic hypertension
and another 7% - by gestational hypertension. Increased duration of prior ART exposure was strongly
associated with higher latent class model-derived trajectories of mean arterial pressure (MAP), a
possible risk factor for pre-eclampsia. In multinomial regression, pregnancies among women with more
than a year of prior ART had almost three times the adjusted odds of a higher MAP trajectory as
pregnancies without prior ART exposure.
DISCUSSION: The findings highlight the potential for continued growth in the hypertension and CVD
burden in Haiti, as well as unmet need for prevention, screening, and quality treatment services, among
both the general urban population and among HIV patients specifically. In addition to secular trends in
these conditions, the increase in cumulative exposure to ART might further fuel the rise in hypertension
and CVD in settings with high prevalence of HIV, such as urban Haiti. Further research is needed into
multimodal interventions and facility- and community-based long-term care models, increasingly for
multimorbidity, among mobile urban slum community residents, with consideration of possible network
effects. Quality of hypertension screening is also of importance, as white-coat and masked
hypertension, as well as potential measurement error and natural blood pressure variability, may
complicate the identification of true cases, in particular on the lower part of the age spectrum. Facilityand community-based programs have an opportunity to meaningfully improve individual and population
health through expanding existing HIV services to encompass hypertension and broader NCD care, and
through leveraging community health workers to reach families and networks in need of prevention,
screening, and management services.
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CHAPTER 1. INTRODUCTION
BACKGROUND
Globally, urban areas with high concentrations of slums present a rapidly growing demographic
and population health challenge due to the confluence of disadvantage resulting from environmental
factors, lack of basic infrastructure, and extreme poverty. Despite increasing recognition of noncommunicable disease (NCD) mortality and morbidity as a barrier to poverty alleviation and
development in lower- and middle-income countries (LMICs), there remain knowledge gaps about
NCDs, their risk factors, and access to NCD care among underserved urban slum populations. In order
to effectively prevent and treat hypertension in fast-changing, resource-poor settings with overlapping
non-communicable and infectious health crises,1 it is necessary to better understand the epidemiology
of hypertension in urban LMIC populations with high concentration of slum communities, and
specifically among people living with HIV (PLWH).
GLOBAL CVD LANDSCAPE AND TARGETS
Cardiovascular disease (CVD) is a leading cause of NCD death worldwide. In 2016, 17.9 million
deaths (31% of all deaths) were attributed to CVD. Of all NCD deaths, 31.5 million (78%) took place in
LMICs, and 46% of these deaths were premature (i.e. below the age of 70).2 Recognizing the human,
economic, and social toll of NCDs, the WHO is targeting 25% reduction in mortality from four major
NCDs, including CVD, by 2025, and improvements on major NCD risk factors, such as tobacco use, poor
diet, physical inactivity, hypertension, and obesity.3 Hypertension in particular, responsible for over
40% of deaths globally from CVD, chronic kidney disease, and diabetes,4 merits close attention and has
been similarly targeted by the WHO for a 25% reduction between 2010 and 2025.5
CVD AND HYPERTENSION IN HAITI
With a population of 10.5 million, Haiti is the poorest country in the Western Hemisphere and
ranks 163rd in the world with respect to human development index.6 Haiti’s health and development
1

challenges were exacerbated by a devastating 2010 earthquake, in the aftermath of which substantial
attention has been paid to immediate public health crises of communicable nature, such as the cholera
epidemic, with few resources for NCDs. Sparse data from the Global Burden of Disease (GBD) Project7
identify hypertensive and ischemic heart disease, and stroke among the largest drivers of mortality
(Figure 1) and disability-adjusted life years (DALYs) nationally. Among risk factors, the burden of DALYs
attributable to high blood pressure is second only to the not unrelated dietary risks.8
To date, hypertension research in Haiti was largely focused on rural residents,9-13 and attendees of
health facilities,12-15 even as evidence supports greater hypertension burden in urban settings in
developing countries.16 Studies on random urban community samples in Haiti reported adult
hypertension prevalence of 47% (using single-day measurement in 2006)17 and 17% (using two-day
measurement in 2015-16);18 a similarly broad range was found in convenience samples (24% - 44%).1015,19

A recent global review of blood pressure trends reported a slight increase in blood pressure levels

among Haitians in the last four decades, in contrast to decreases in the Latin America and Caribbean
region, and in the neighboring Dominican Republic.20
Haiti’s true burden of CVD and hypertension is not known due to a lack of recent data. GBD
models of the causes of death for the country are limited to five years of vital registration data
(between 1981 and 2004), four years of police records, and several small, verbal autopsy and sibling
history studies, all conducted prior to 2005.7 The recent global review of blood pressure trends
included no data from Haiti, and based its estimates for the country on a model combining blood
pressure data from other countries in the region, and covariates reflecting each country’s social and
demographic characteristics.20 However, available CVD data from Haiti indicate alarming patterns:
young women are overrepresented among congestive heart failure patients (largely due to peripartum
cardiomyopathy),21,22 and Haiti has one of the highest stroke mortality rates in the Latin
America/Caribbean region, and more than twice that of the neighboring Dominican Republic.23
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CVD AND HYPERTENSION AMONG PEOPLE LIVING WITH HIV IN LMICs
The increase in NCDs is occurring against the backdrop of substantial burden of communicable
diseases such as HIV (1.9% prevalence in metropolitan Port-au-Prince).24 HIV is increasingly recognized
as a major CVD risk factor25 and the co-occurring epidemics are of particular concern in Haiti, which
has the world’s highest CVD burden attributable to HIV outside of sub-Saharan Africa.26
Since the introduction of antiretroviral treatment (ART), HIV has become a treatable chronic
condition, with life expectancy approaching that of the general population.27 As they live longer, PLWH
become more susceptible to conditions associated with aging, lifestyle, and duration of HIV infection,
as well as possible ART side effects,28-32 such as CVD. PLWH also tend to experience cardiovascular
events at ages younger than general population.33 Meta-analyses report the risk of CVD to be about
twice as high among PLWH than HIV-negative populations,26,30 and higher among persons on ART than
those not receiving treatment.30 Hypertension prevalence is also higher among HIV-positive adults
than those without the infection,34-36 and related complications may be more frequent, compared with
persons without HIV and with similar blood pressure levels.37
Both HIV and ART may increase one’s risk of CVD through two major pathways, individually or
in combination: 1) HIV/ART may increase the occurrence of a traditional risk factor for CVD (e.g. more
severe dyslipidemia); and 2) HIV/ART may operate via pathogenic processes associated with CVD in
ways not involving traditional risk factors (e.g. immune-related inflammation).38 Hypertension in
particular may be induced by HIV and ART via factors including chronic HIV-associated inflammation,
immune suppression and reconstitution, impairment in endothelial function and imbalance in the
renin-angiotensin system, renal disease, dyslipidemia, and lipodystrophy.39-42
Prevalence of hypertension among PLWH in LMICs has been reported to range from 9% to
46%.43 In one study in Tanzania comparing HIV-negative controls to PLWH on ART and ones not on
ART, those on ART had over twice the odds of hypertension compared to HIV-negative persons, while
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ART-naïve PLWH had 65% lower odds. Hypertension prevalence was highest among patients whose
previously low CD4 counts increased the most on ART, pointing to hypertension potentially induced by
chronic immune activation and inflammation.36 Low nadir CD4 count was also found to be a strong risk
factor for sustained hypertension among ART patients in Norway.44 A study of incident hypertension
among PLWH initiating ART in Uganda found much higher levels of hypertension than those reported
from resource-rich countries, including among young PLWH <30 years old.45 The possible link between
low blood pressure and morbidity and mortality46-51 is also noteworthy among PLWH, due to the
association of certain opportunistic infections such as histoplasmosis with low blood pressure levels.52
The confluence of pathways towards CVD risk among PLWH, especially in LMIC settings where
CVD care and prevention may be concentrated in higher-level medical facilities,53 and among young
PLWH, demands close attention to hypertension – an easily measured, major modifiable risk factor for
CVD. With ongoing ART scale-up, including in LMICs where over 70% of the world’s PLWH reside,
health outcomes among PLWH will largely be shaped by NCDs such as CVD.29
HYPERTENSION AMONG PREGNANT HIV-POSITIVE WOMEN
Pregnant HIV-positive women in low-resource settings may be particularly vulnerable to CVD.
Hypertensive disorders of pregnancy, including chronic and gestational hypertension, as well as
eclampsia and pre-eclampsia - a major cause of maternal and perinatal morbidity and mortality, affect
about 10% of pregnancies worldwide.54 In Latin America and the Caribbean, these conditions are
estimated to be responsible for over a quarter of maternal deaths55 and have been documented at
substantial rates among HIV-positive pregnant women.56 In Haiti, high rates of antepartum eclampsia,
pre-eclampsia,57,58 and postpartum eclampsia57,59 have been documented. Haiti’s maternal mortality
rate is the highest in the Western Hemisphere with an estimated 521 deaths for every 100,000 live
births, almost 10 times as high as in the neighboring Dominical Republic.60
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Risk factors for pre-eclampsia, such as obesity and prior hypertension, are common among
Haitian women of reproductive age.24,61 High prevalence of HIV in this population (2.3%)24 presents an
additional complication, although findings on the association between HIV infection and ART history,
and hypertensive disorders of pregnancy, have been mixed.56,62-74 HIV infection has also been
hypothesized to decrease the risk of pre-eclampsia via HIV-associated immunosuppression possibly
reducing the risk of pre-eclampsia-associated immune hyper-reactivity.75 Altogether, however,
maternal morbidity and mortality are a significant concern in Haiti and sustained background
prevalence of HIV may further contribute to increased health risks in pregnancy.
HYPERTENSION IN URBAN SLUM SETTINGS
Almost 1 billion people worldwide are estimated to live in slums, a number projected to reach
2 billion by 2030 76. As of 2014, 74% of urban Haitians were considered to reside in “slum households”,
defined as lacking one of more of the following conditions: access to improved water, access to
improved sanitation, sufficient living area, and durability of housing.77,78 These disadvantages are often
compounded by the lack of tenure security and scarce access to health services.76,79 Substantial
background prevalence of HIV is often observed in slum settings: in 2008-09, HIV prevalence was twice
as high in two Nairobi slums as in non-slum urban or rural areas of Kenya.80 In Port-au-Prince, a 201415 community testing program reported HIV prevalence of 2.7% among slum residents 10-24 years
old;81 higher than adult and youth prevalence in metropolitan Port-au-Prince82 and nationally.82,83 In
2012, HIV prevalence was found to be particularly high (3.9%) among residents of camps for those
displaced by the 2010 earthquake,82 highlighting the vulnerability to the infection among the poor
living in cramped, unstable housing settings.
Estimates of hypertension prevalence in slum settings in India, Nigeria, Kenya, Brazil, and Peru
have ranged from 12% to 52%,84-92 although diversity of sampling methods complicates comparisons.
Awareness of having hypertension was low (5% - 65%),85-92 as was hypertension control (4% - 29%).85-

5

87,92

Some studies observed disparities by gender: hypertension prevalence was greater among men in

studies that measured blood pressure,85,86,88,91 but in a study relying on self-report, more women
reported the condition,93 possibly due to differences in care-seeking behavior. Disparities were also
reported further down the care continuum: in a Nairobi slum, 31% of women with hypertension were
aware of it (versus 12% of men), but among those receiving hypertension treatment, a greater share of
men attained hypertension control (36% versus 14% of women).92
Underrepresentation of persons who migrate in and out rapidly,94 even though recent inmigration status may be linked to poor outcomes,95 is a common bias in studies of slum health, and
available data should be viewed alongside this limitation. In Haiti, where health challenges are
exacerbated by natural disasters and periodic intensifications of violence, substantial internal
migration signals particular vulnerability of individuals and health systems in rapidly urbanizing and
expanding slum settings.
SPECIFIC AIMS
The study sought to characterize the burden of hypertension and unmet healthcare needs in an
urban slum community in Port-au-Prince and among persons receiving HIV care at a clinic adjacent to
the slum community. The study hypothesized that substantial hypertension levels would be observed
in the three examined populations (random community sample, patients with newly diagnosed HIV
initiating ART, and HIV-positive pregnant women), and that there would be low levels of hypertension
awareness and/or control. The following aims were specified:
Aim 1: Estimate the prevalence and describe individual- and household-related correlates of
hypertension, as well as its care continuum, among residents of four slum communities in
Port-au-Prince.
Aim 2: Estimate the prevalence and incidence of hypertension, and characterize longitudinal
hypertension status following hypertension onset, among persons with newly diagnosed HIV

6

initiating ART at an HIV clinic adjacent to and serving the same slum communities and broader
Port-au-Prince.
Aim 3: Assess trends in the prevalence and incidence of gestational and chronic hypertension, and
describe longitudinal blood pressure patterns, among HIV-positive pregnant women with and
without prior ART exposure in a prevention-of-maternal-to-child-transmission (PMTCT)
program serving the same slum communities and broader Port-au-Prince.
OVERVIEW OF THE DISSERTATION
RESEARCH SETTING
Port-au-Prince and slum communities
Port-au-Prince is the capital of Haiti with estimated population of 987,310 in the city proper, and
2,759,991 in its metropolitan area.96 Village (Cité) de Dieu, Cité Plus, Cité l’Eternel, and Martissant
Littoral are four neighboring slum communities in downtown Port-au-Prince, covering a geographic
area of 0.96 km2.97 (Figure 2) The area is below sea level, at the bottom of a basin surrounded by
deforested mountains, and is vulnerable to flooding. Since the 1950s, this coastal area has developed
into informal, increasingly overcrowded settlements characterized by poor access to sanitation, clean
water, and electricity. After the January 2010 earthquake which left approximately 1.5 million Haitians
homeless, almost 280,000 people from outside Port-au-Prince sought shelter in the city, often in tent
camps adjacent to the slum communities.98-100 In the following years, many camp residents relocated
into the slum communities,101 further driving crowding. In recent decades, the communities have
suffered political and gang violence,102-105 which further limited access to social and health services.
In 2016, the communities’ estimated population size was 55,622, for a density of 58,000
persons/km2,97 over twice as high as Port-au-Prince overall.96 As is common in urban centers,106,107
women outnumber men both in the metropolitan area96 and in the slum communities examined here,
largely due to overrepresentation of young women ages 15-34 compared to Haiti as a whole.97
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GHESKIO
Founded in 1982, GHESKIO (Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic
Infections) is a nongovernmental organization and the largest provider of HIV, PMTCT, and
tuberculosis services in Haiti.108-111 Along with primary care and sexual health services, GHESKIO
receives over 100,000 patient visits each year. In addition to free clinical services, GHESKIO is actively
engaged in research and clinician training, as well as social services, operating a school and providing
job training for community members.
In the aftermath of the 2010 earthquake, GHESKIO’s campus, adjacent to the slum communities
under study, (Figure 2) became a refugee camp for over 6,000 individuals and an emergency field
hospital, while continuing to provide services to thousands of patients relying on the facility for HIV
and tuberculosis care.100 In the years since, GHESKIO has increasingly conducted public health research
and provided services directly in the surrounding communities, including tuberculosis case-finding,112
screening for HIV and sexually transmitted infections,81 as well as cholera vaccination.113 GHESKIO has
also taken steps to counter the increasing NCD burden, with the goal of establishing a dedicated
hypertension clinic. Many HIV-positive cohorts at GHESKIO consist of majority slum residents, including
57% of a 2014-2016 program for stable patients receiving ART.
DATA SOURCES
Aim 1 was based on primary, cross-sectional data collection among households and adults
residing in four slum communities in Port-au-Prince (Village [Cité] de Dieu, Cité Plus, Cité l’Eternel, and
Martissant Littoral; Figure 2). A population-representative, multistage randomized survey was
conducted between July and October 2016. Global positioning system (GPS) data and high-resolution
satellite images were used to establish a sampling frame, as survey areas lacked street addresses or
census data. Survey design and procedures have been described in detail previously.97
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Aims 2 and 3 used secondary, longitudinal data derived from GHESKIO’s electronic medical
records (EMR). Aim 2 data were for participants of a clinical trial based at GHESKIO: adults newly
diagnosed with HIV and with no prior ART exposure, and with CD4 counts ≤500 cells/ml, who were
randomized to same-day or deferred (standard of care) ART initiation. The trial lasted from August
2013 to October 2015, with additional follow-up data until July 2017.
Aim 3 data were for pregnant HIV-positive women enrolled in GHESKIO’s PMTCT program
between January 2007 and December 2016, with follow-up data until July 2017. Pregnancies included
in the analysis had to have a known delivery date and at least 12 weeks PMTCT follow-up, and not
have ended in stillbirth, abortion, or maternal death.
Figure 3 illustrates the timeframes covered by each aim’s data.
ANALYTIC METHODS
Aim 1 methods accounted for complex survey design, survey nonresponse, and clustering of
participants within neighborhood blocks, GPS points, and households. Hypertension prevalence in the
population-representative community sample was standardized to the world population. Sex-stratified
logistic regression examined associations between participant characteristics and hypertension. A care
continuum characterized prior hypertension screening, diagnosis, and treatment status.
Aim 2 described prevalence and incidence of hypertension among newly diagnosed with HIV
patients initiating ART. Competing risk methods were used to estimate cumulative incidence and
assess factors associated with incident hypertension, while accounting for death as a competing event.
Cox proportional hazards models were used to examine the association between baseline blood
pressure and mortality. A heatmap visually characterized patient-level trajectory of hypertensive
status following hypertension onset, stratified by severity of hypertension at onset.
In aim 3, prevalence and incidence of hypertension, with a breakdown into gestational and
chronic hypertension, were described over a 10-year period among pregnant HIV-positive women.
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Latent class models were used to identify distinct trajectories of mean arterial pressure in pregnancy,
and multinomial ordinal logistic regression examined factors associated with higher trajectories.
PUBLIC HEALTH SIGNIFICANCE
The work completed under the above aims has begun to fill critical knowledge gaps on the
epidemiology of hypertension in a setting with high prevalence of HIV and among PLWH specifically,
allowing local providers to better design and target prevention, screening, management and treatment
activities with the limited resources available. Findings may also inform broader efforts by public
health authorities, researchers, and urban planners to prevent and address CVD risk in rapidly growing,
dense, and disadvantaged settings such as urban areas with high concentrations of slum communities.
Aim 1 work is the first in the region to employ a complex, GPS-based sampling scheme to
examine hypertension and other NCD risk factors in a slum population that is difficult to systematically
and representatively study. This aim also extends the concept of a care continuum, commonly applied
to HIV care indicators, to characterize access to and continuity of care for a non-communicable
condition such as hypertension.
Estimation of hypertension prevalence and incidence in two multi-year clinical HIV cohorts in
aims 2 and 3, along with longitudinal blood pressure and hypertensive status patterns, provides
important insights into hypertension burden and opportunity for intervention with respect to
prevention, management, and treatment among patients engaged in lifelong medical care for HIV.
Assessment of ART exposure as a correlate of blood pressure patterns adds LMIC insights regarding
contributions of ART and immune reconstitution in the genesis of hypertension. As life expectancy for
PLWH approaches that of HIV-negative individuals, and cumulative ART exposure lengthens, HIV care
and treatment programs can play a critical role in CVD prevention, screening, management and
treatment among populations otherwise lacking access to such services. This study’s findings can
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inform the needs of established HIV programs with respect to possible shifts to provide NCD care to
their patient populations and communities more broadly.
The aims characterize the hypertension burden and related healthcare needs of
underprivileged, dynamic communities with limited access to NCD prevention, screening,
management, and treatment, against a background of inadequate population health monitoring,
shrinking health funding, and intertwining communicable and non-communicable health crises.
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Figure 1. Mortality by cause, all ages, Haiti 2017.

Source of the image: Global Burden of Disease (GBD) Project
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Figure 2. Satellite image of the four slum communities under study and the main GHESKIO campus
(Imagery © 2017 DigitalGlobe, Inc.).

Figure 3. Timeframes and type of data sources included in the dissertation.
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CHAPTER 2: HYPERTENSION PREVALENCE AND RISK FACTORS AMONG
RESIDENTS OF FOUR SLUM COMMUNITIES: POPULATIONREPRESENTATIVE FINDINGS, 2016 (AIM 1)
ABSTRACT
Objectives: To estimate the prevalence of hypertension and its risk factors among adult residents of four
slum communities in Port-au-Prince.
Methods: Cluster area random sampling was used to select adults for a health and demographic survey,
including anthropometric measurements. Hypertension was defined as systolic blood pressure ≥ 140
and/or diastolic blood pressure ≥ 90 mmHg using single-day measurement, or self-reported current
hypertension treatment prescribed by a clinician, and was age-standardized to WHO world population.
Correlates of hypertension were examined using sex-stratified logistic regression.
Results: Overall, 20.3% of adults had hypertension (28.5% age-standardized), including 22.3% of men
and 18.9% of women. Three percent of participants reported current hypertension treatment, and
49.5% of them had their hypertension controlled. Overweight/obesity (BMI ≥ 25) was the most common
risk factor (20.6% among men, 48.5% among women), while smoking was less common (11.8% and
3.9%, respectively). Increasing age and hypertension prevalence in immediate surroundings were
associated with greater odds of hypertension. Among men, having in-migrated in the 3 years prior
(versus >3 years) was also associated with hypertension (adjusted odds ratio [aOR] = 3.3, 95%
confidence interval [CI]: 1.8-6.2); as was overweight and obesity (aOR = 1.9, 95% CI: 1.1-3.3, and aOR =
5.7, 95% CI: 2.5-13.2, respectively) and non-receipt of needed medical care in the preceding six months
(aOR = 2.8, 95% CI: 1.3-5.9) among women.
Conclusions: Hypertension prevalence was high across the age spectrum, in addition to substantial
levels of overweight/obesity and unmet healthcare needs. It is important to better understand the
possible effects of intraurban migration and environmental risk factors on hypertension, and ensure that
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benefits of increasingly cost-effective prevention and treatment programs extend to slum community
residents.
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INTRODUCTION
Non-communicable diseases (NCDs) such as cardiovascular disease (CVD) are the leading cause of
death and disability, and on the rise in low- and middle-income countries (LMICs), where three quarters
of all NCD deaths occur.1 The World Health Organization (WHO) targets a 25% global reduction in CVD
mortality, as well as hypertension, by 2025.1 However, achievement of these goals may be hampered by
a scarcity of data on the burden of NCDs and their risk factors such as hypertension in many LMICs.
Rapidly growing urban slums, with worldwide populations estimated to reach 2 billion by 2030,2 are
an important setting with respect to the increasing CVD burden, with residents vulnerable to poor
health outcomes because of a confluence of poverty, inadequate healthcare access, and environmental
and social disadvantage. With their unique social and physical environment, and possible associated
neighborhood effects on health, slum settings merit concerted research into their health status and
needs.3
CVD is increasingly common in Haiti, the poorest country in the Western Hemisphere, where 74%
of the urban population live in slum settings.4 Adult hypertension prevalence in Port-au-Prince has been
reported as high as 47%5 and hypertensive heart disease is one of the fastest growing causes of death
nationally.6 Haiti has one of the highest stroke mortality rates in the Latin America/Caribbean region,
and more than twice that of the neighboring Dominican Republic.7 No slum-specific estimates of
hypertension prevalence are available from Haiti, but research from slum settings in other countries has
reported a wide range of estimates (12% to 52%),8-17 often low awareness of having hypertension (5% to
65%),9-16 and poor hypertension control (4% to 29%),9-11,16 though most available data were limited by
convenience sampling.
This paper characterizes for the first time hypertension and its risk factors in a representative
sample of adult residents of four Port-au-Prince slum communities.
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METHODS
Setting
GHESKIO (Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections) is a nongovernmental organization and the largest provider of HIV and tuberculosis services in Haiti,18 and
neighbors large slum communities in Port-au-Prince. From July to October 2016, GHESKIO collaborated
with Cornell University, City University of New York, and University of Minnesota, on a survey in four of
these neighborhoods: Village (Cité) de Dieu, Cité Plus, Cité l’Eternel, and Martissant Littoral, with an
estimated population of 55,622.19 Most residents live in extreme poverty, in crowded conditions with
limited access to education, sanitation, and medical care.20,21 No systematic demographic studies or
general health surveys had been previously conducted in these communities.
Study design
Design of this cross-sectional survey is described in detail in the Appendix. Using cluster area
random sampling and high-resolution aerial images from the DigitalGlobe Foundation,22 111 geospatial
waypoints were randomly selected across the four adjacent neighborhoods based on the estimated
population density of each neighborhood. At each waypoint, fieldworkers surveyed five nearest
households, and two adults were randomly selected from each household’s resident roster for an
additional survey. Households were defined as a person or persons, related or unrelated, who live
together in a residential structure, make common provisions for food, and regularly take their food from
the same pot.23 Eligible household members had to be ≥ 18 years old and have slept in the household at
least once in the past two nights.
Up to three attempts were made to interview households and individuals, and verbal consent was
obtained from participants after study goals, content, risks, and voluntary nature were discussed. Due to
literacy gaps in the study population, written consent was waived, and the consent form was read out
loud to participants by fieldworkers.
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Data collection
Household surveys were paper-based and included questions on household composition, living
conditions, and mortality. Individual surveys were administered on an encrypted Android tablet and
included sociodemographics, migration history, disease symptoms and diagnoses, healthcare utilization,
and select NCD risk factors. All surveys were in Haitian Creole, after translation from and backtranslation into English. Anthropometrics (height and weight without shoes, waist circumference) and
blood pressure were also recorded. Blood pressure was measured three times on the left arm using a
Panasonic model EW3109W monitor, with three cuff sizes based on upper arm circumference, after
participant was seated for a minimum of 15 minutes.24 I used the mean of the last two readings as the
final blood pressure measurement.
Participants with any systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure
(DBP)≥90 mmHg received basic information about hypertension and were referred to GHESKIO for free
re-screening and medical care. Participants with any SBP ≥ 180 mmHg were escorted to GHESKIO on the
same day.
Data from paper forms were double-entered and reconciled using RedCap (Research Electronic
Data Capture).25 Tablet data were stored in a secure database at GHESKIO. Data were regularly reviewed
for completeness and consistency against paper logs of survey attempts. All data were de-identified for
cleaning and analysis.
Hypertension definition
Hypertension was defined as mean SBP ≥ 140 mmHg or mean DBP ≥ 90 mmHg, or a self-report of
taking anti-hypertensive drugs prescribed by a medical professional, per JNC-VII.26 Stage 2 hypertension
was defined as mean SBP ≥ 160 mmHg and/or mean DBP ≥ 100 mmHg. Among remaining subjects, stage
1 hypertension was defined as mean SBP 140-159 mmHg or mean DBP 90-100 mmHg. Then prehypertension was defined as mean SBP 120-139 mmHg or mean DBP 80-89 mmHg.26 For sensitivity
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analysis, hypertension prevalence was also calculated using the new 2017 American College of
Cardiology (ACC) guidance (elevated BP: SBP 120-129 and DBP < 80 mmHg; hypertension stage 1: SBP
130-139 mmHg or 80-89 mmHg, and hypertension stage 2: SBP ≥ 140 mmHg or DBP ≥ 90 mmHg).27
Risk factor definitions
Body mass index (BMI) was categorized as underweight (< 18.5 kg/m2), normal (18.5 - < 25 kg/m2),
overweight (25 - < 30 kg/m2), and obese (≥ 30 kg/m2).28 Waist circumference > 94 cm and > 80 cm (for
men and women, respectively), corresponding to WHO classification of increased metabolic risk, was
classified as central obesity.29
Psychological distress was assessed for the preceding 30-day period using the Kessler-6
instrument.30 Smoking status was self-reported as smoking on some or all days. Frequency of alcohol use
was self-reported as never, monthly or less, 2-4 times a month, 2-3 times a week, or 4 or more times a
week. For analysis, the variable was dichotomized into at least twice a week versus less. To assess diet,
respondents were asked how many days in a typical week they eat 1) fresh fruit, and 2) vegetables. For
analysis, the mean of both numbers was used.
To reflect unmet healthcare needs, participants were asked whether they needed, but did not get
healthcare at any point in the preceding six months. To represent possible shared genetic and/or
environmental risk factors, hypertension prevalence in each participant’s immediate surroundings was
calculated as proportion of participants with hypertension in the same waypoint, excluding the
participant.
Statistical analysis
Descriptive statistics were used to characterize study participants and the prevalence of
hypertension and its risk factors. Reported p-values are for Rao-Scott chi-square tests for complex
survey samples.
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Sex-stratified logistic regression was used to assess correlates of hypertension, including
sociodemographics and possible risk factors. All variables with bivariate p-values < 0.20 were included in
initial multivariable models, and eliminated by backward selection until all remaining variables had pvalues < 0.05. Dropped variables were then individually added back to further assess possible
confounding. Both models were adjusted for slum neighborhood. All analyses were weighted for
complex survey design and nonresponse. Population-attributable fractions (PAF) for overweight and
obesity were calculated using adjusted odds ratios (aOR) from the final models.
Hypertension prevalence was age-standardized to the world population using the 2000-2025 WHO
standard population data.31
Ethics
This study was approved by institutional review boards at Weill Cornell Medicine, City University of
New York, University of Minnesota, and the Ethics Board at GHESKIO.
RESULTS
Fieldworkers obtained community cooperation and accessed 109 of 111 waypoints, resulting in
random selection of 545 households, of which 525 (96.3%) completed the household survey. Of 993
randomly selected adults in these households, 894 (90.0%) completed the individual survey and 99.1%
of them (886/894) had their blood pressure measured.
Sociodemographics and health status
More than half of adults were 30 years old or younger, with a median age of 28 years (IQR: 22-39).
Over a third (36.0%) had no more than primary education, 40.1% had no income, and 40.0% moved to
the current community in the past three years. Most residents who migrated to the community had
previously resided in another slum in Port-au-Prince (36.3%) or elsewhere in Metropolitan Port-auPrince (26.6%). The main reasons for migrating included desire to join relatives or friends, work, and
education. In the past year, 21.7% of adults spent over a month at a time away from the community. A
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fifth of adults (20.2%) reported having a health problem that keeps them from working and a quarter
(26.3%) did not receive needed healthcare in the six months prior. Approximately a third (35.6%; 26.8%
of men and 41.8% of women) had seen a medical practitioner in the year prior. (Table 1)
Blood pressure levels and hypertension prevalence
Overall, 20.3% of adults (22.3% of men and 18.9% of women, p = 0.425) had hypertension per JNCVII definition. Age-standardized prevalence was 28.5%. Restricted to blood pressure measures, 12.6% of
adults had hypertension stage 1 and 6.2% - stage 2. An additional 27.5% had pre-hypertension. (Table 2)
Applying the 2017 ACC definitions, 36.8% of adults had hypertension (17.0% - stage 1 and 18.8% - stage
2) and 10.5% had elevated blood pressure.
Mean SBP and DBP increased with age, reaching 133/85 mmHg and 132/83 mmHg among men and
women, respectively, at age 45 and above. (Figure 1) Similarly, prevalence of hypertension increased
with age, with 7.1% of adults ages 18-24 having hypertension (13.5% of men and 3.7% of women, p =
0.013) and 43.6% of adults aged ≥ 45 years (48.8% of men and 39.6% of women, p = 0.125). Prevalence
of hypertension was higher among men than women, despite markedly lower obesity levels among men
across the age spectrum. (Table 2, Figure 2)
Prevalence of hypertension risk factors
Overall, 36.9% of adults were overweight or obese (20.6% of men and 48.5% of women; p < 0.001).
Many individuals ate at least one fried meal per day (68.7%) and always or often added salt (33.2%).
Fresh fruit/vegetables were consumed on a median of 1.6 days per week (IQR: 0.7-2.8) and soda or
sugary drinks – on a median of 2.1 days (IQR: 0.5-6.1). Only 7.2% of adults were smokers (11.8% of men
and 3.9% of women) and 17.7% drank alcohol at least twice a week (32.1% of men and 7.4% of women).
Almost two thirds of adults (65.7%) lived in households which cook indoors over charcoal, wood, or fire.
Hypertension awareness and care continuum
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Most adults (62.0%) had had blood pressure measured previously. Among persons with
hypertension per actual blood pressure measures (excluding self-reported treatment), 36% of men and
44% of women had previously been diagnosed, and 4% of men and 12% of women reported taking antihypertensive treatment prescribed by a clinician. (Figure 3)
Among all previously diagnosed adults, regardless of current hypertension status, 8.4% of men and
20.5% of women reported such treatment. Nevertheless, 42.1% were hypertensive per actual blood
pressure measures, as were 50.5% of adults reporting current anti-hypertensive treatment prescribed
by a clinician. In addition to patients reporting clinician-prescribed treatment alone or in addition to
herbal treatment (67.8% of those reporting any treatment), 32.2% of patients reported receiving only
herbal or self-prescribed treatment.
Correlates of hypertension
In multivariable analyses, increasing age was associated with increased odds of hypertension, with
an adjusted odds ratio (aOR) = 1.4 (95% confidence interval [CI]: 1.2-1.6) for each 5-year increase in age
among men and aOR = 1.3 (95% CI: 1.2-1.5) among women. Each 5 percentage point increase in
waypoint-level hypertension prevalence was also consistently associated with increased odds of
hypertension (aOR = 1.4 [95% CI: 1.2-1.7] among men, aOR = 1.3 [95% CI: 1.2-1.4] among women).
Overweight and obesity were only associated with hypertension among women (aOR = 1.9, 95% CI: 1.13.3, and aOR = 5.7, 95% CI: 2.5-13.2, respectively), as was non-receipt of needed healthcare in the
preceding six months (aOR = 2.8, 95% CI: 1.3-5.9). Migration history was a statistically significant
correlate of hypertension among men (aOR = 3.3, 95% CI: 1.8-6.2, for three years or less in the
neighborhood versus more than three years). (Table 3)
The adjusted PAF of hypertension due to overweight and obesity was 2.2% among men and 64.8%
among women.
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Persons with hypertension tended to live in waypoints with greater hypertension prevalence
(excluding self: 30% versus 15% for those without hypertension). They were more likely to have been
unable to access needed care in the six months prior (36.7% versus 22.5%). There was no appreciable
difference in nutritional practices by hypertension status. (Supplemental Table 1)
DISCUSSION
I found a high prevalence of hypertension in a population-representative sample of residents of
four slums in Port-au-Prince, including among young adults, along with large treatment gaps and
potentially unique risk factors for the condition. Hypertension appears to cluster, possibly suggesting
presence of a social network effect, which could be leveraged in the development of hypertension
management programs in this setting.
Overall, 20.3% of adults were classified as having hypertension (age-standardized prevalence of
28.5%). This estimate is higher than most of those reported in other countries with comparable slumbased surveys,12,13,15,16 but lower than in most research from non-slum settings in Haiti (generally
convenience samples32-38 and often from healthcare settings).32-35,38 Our estimates are similar to those
from a random 2015-16 urban sample in an area near Port-au-Prince (17.1%),39 but lower than those
from two other randomly selected urban samples in Haiti. In 2002-03, hypertension prevalence was
estimated at 47.0% in Port-au-Prince residents aged 20 and above,5 while the 2016-17 Demographic and
Health Survey (DHS) estimates for ages 35-64 across urban Haiti were 49.2% among women and 40.5%
among men,40 compared to 35.0% and 36.2%, respectively, in this age group in our sample. The higher
prevalence of pre-hypertension, overweight, and obesity in our study signals a potential for increases in
the burden of hypertension in the slum communities.
Notably, hypertension in our study was common among young adults, including 11.1% of 18 to 30year-olds. This is much higher than the 5.1% prevalence in a 2011-14 population-representative sample
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of black US Americans ages 20-30,41 though population-representative surveys in Rwanda,42 Uganda,43,44
and Tanzania44 also found high hypertension prevalence among young adults.
Missed opportunities to provide hypertension diagnosis and care were common in our population.
Over a third of hypertensive adults had sought medical care in the recent past and four in ten had
previously been told they had the condition (similar or slightly lower than awareness rates previously
reported in Haiti).37,38 Furthermore, few persons previously diagnosed with hypertension were receiving
treatment (less than half of the proportion on treatment reported by the 2016-17 DHS for urban Haiti)40
and only half of them had the condition controlled (similar to another Haitian sample).36 Many of these
missed opportunities may have occurred because Haitian healthcare services remain focused on
communicable conditions, and have not yet adapted to the growing burden of diagnosing and treating
NCDs. To maximize patient engagement as access to treatment expands, a diversity of beliefs and
preferences should also be considered, as some Haitians may consider hypertension a natural state,
while others may seek herbal treatments.45
Unique risk factors may contribute to hypertension in this population, particularly for men, among
whom only 2.2% of hypertension cases were attributable to overweight/obesity. Data from Tanzania
and Uganda has also shown a low PAF of hypertension for above-normal BMI and central obesity,44 and
similarly lower for men than women (personal communication). While data on many possible risk
factors of interest for slum communities, such as stress, exposure to adverse intrauterine
environment,46,47 HIV and antiretroviral treatment status,48,49 and lead exposure50 were not available, I
found strong associations with social determinants such as non-receipt of needed medical care and
recent migration.
Internal migrants are a vulnerable population with sometimes worse health outcomes than host
populations.51 Studies have reported higher blood pressure and/or hypertension levels among recent
arrivals,52-54 though some research suggests worsening risk profiles with increased duration of exposure
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to urban lifestyle and environment.55-57 An association between migration and increased blood pressure
among men only has also been observed previously, possibly due to greater weight gain;58 drop in
physical activity;59 higher cumulative number of moves, or migration in search of employment and/or
alone.57 The latter may be linked with CVD via depression.60,61 Most published research, however, has
examined rural-urban migration,52-54,56-59,62-65 while the most recent move was intraurban for the
majority of migrants in our sample. Future studies of slum communities should assess risk factors
specifically with respect to intraurban mobility.3
Our study also suggests that hypertension programs could be informed by possible social network
effects, as indicated by the observed clustering of persons with hypertension. Given Haiti’s strong
community bonds,66 offering prevention knowledge and treatment to patients in this setting may
facilitate health promotion in these individuals’ immediate environments.
To optimize resource allocation in low-resource settings, it is important to minimize patient
misclassification. Although hypertension diagnosis ideally should be based on blood pressure
measurements from two different days,67,68 this requirement can constitute a barrier to timely diagnosis.
Simplified screening protocols,69 region-specific non-laboratory cardiovascular risk scores,70 and low-cost
laboratory measures such as urine dipstick tests for proteinuria67 have been proposed to sustainably
improve single-visit assessments of cardiovascular risk, though in some low-resource settings, treating
everyone with hypertension may be more cost-effective than any risk stratification.67
Community health workers may be a valuable resource for hypertension control in slum settings, as
demonstrated by SCALE UP, an intervention in a community of 35,000 residents in Nairobi, Kenya.71
Combining door-to-door hypertension screening and awareness activities, group and text message
adherence support, and patient and provider treatment incentives, the intervention saw high
participation rates72 at a cost of approximately 1 USD per person per year.71 Community education,
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complementing individual prevention and therapeutic focus, is critical to produce population-level
cardiovascular risk improvements in dynamic slum communities with a lot of in- and out-migration.67
Finally, successful hypertension control programs in impoverished settings will also require efficient
long-term management of a range of chronic conditions, including strategies such as task sharing, and
continued availability of funding mechanisms and affordable medications in primary health settings.73
Major medications for hypertension and other chronic diseases remain largely unavailable and/or
unaffordable in low-income countries.74
Strengths of this study include its population-representative design and high completion rate,
enabling us to publish rare weighted estimates of hypertension prevalence and its risk factors for urban
Haiti, expanding on research from older research and/or samples with narrower age groups.5,39,40 With a
focus on slum communities and a range of risk factors, this work offers a comprehensive view of
hypertension in this unique setting and contributes to the limited population-representative slum
hypertension studies. The study adhered to the WHO STEPS blood pressure measurement guidelines24
and the JNC-VII hypertension definition,26 facilitating comparisons with other research.
Among limitations, a single-day blood pressure measurement is likely to overestimate hypertension
prevalence.68 Because of the length of the survey, it was not possible to include validated scales for
assessment of complex concepts such as diet, or assess physical activity.
In conclusion, in our population-representative sample of adult slum residents in Port-au-Prince,
substantial hypertension rates were found across the age spectrum. As slum populations worldwide
continue to grow, it will be critical to better understand the unique risk factors for hypertension and
cardiovascular disease in these communities, including strong social networks, environmental risk
factors, and intraurban migration. In addition, health systems will need to adapt to provide costeffective primary and secondary prevention programs to slum residents.
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TABLES AND FIGURES
Figure 1. Mean systolic and diastolic blood pressure and 95% confidence interval, among slum
community residents, by age and sex, Port-au-Prince, Haiti, 2016.

Figure 2. Prevalence of hypertension, pre-hypertension, and obesity among slum community
residents, by age and sex, Port-au-Prince, Haiti, 2016.

36

Figure 3. Hypertension care continuum among slum community residents, by sex, and hypertension
status per actual blood pressure measures, Port-au-Prince, Haiti, 2016.

Table 1. Characteristics of slum community residents, by sex, Port-au-Prince, Haiti, 2016.
Overall
N (weighted %)

Men
N (weighted %)

Women
N (weighted %)

894 (100%)

350 (41.6%)

544 (58.4%)

Village de Dieu

271 (27.7%)

106 (30.6%)

165 (25.7%)

Cité Plus

165 (13.2%)

66 (16.8%)

99 (10.6%)

Martissant Littoral

254 (24.3%)

103 (24.6%)

151 (24.1%)

Cité Eternel

204 (34.8%)

75 (28%)

129 (39.7%)

Median (IQR)

28 (22-39)

30 (23-41)

27 (22-39)

18-24 years

263 (34%)

96 (28.6%)

167 (37.8%)

25-30 years

212 (23%)

79 (23.5%)

133 (22.6%)

31-44 years

263 (23.5%)

112 (26.6%)

151 (21.4%)

≥ 45 years

156 (19.5%)

63 (21.3%)

93 (18.2%)

Total N (weighted %)
Sociodemographics
Neighborhood

Age

Highest education level attended
No formal education

68 (7.3%)

11 (3.8%)

57 (9.8%)

Primary

286 (28.7%)

99 (28.7%)

187 (28.8%)

Secondary

461 (54.1%)

200 (56.2%)

261 (52.6%)

78 (9.9%)

39 (11.3%)

39 (8.8%)

Married or cohabitating

427 (45.4%)

168 (49.2%)

259 (42.8%)

Single

370 (45.2%)

161 (45.6%)

209 (44.9%)

97 (9.4%)

21 (5.2%)

76 (12.3%)

Higher
Marital status

Widowed, divorced, or separated
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Income per day
None

308 (40.1%)

91 (26.0%)

217 (50.1%)

Up to 100 goudes

178 (17.7%)

53 (16.0%)

125 (18.9%)

More than 100 goudes

385 (42.2%)

192 (58.0%)

193 (31.0%)

Less than a year

137 (14.7%)

44 (10.3%)

93 (17.7%)

1-3 years

244 (25.3%)

95 (23.9%)

149 (26.3%)

> 3 years but not whole life

230 (28.2%)

83 (27.4%)

147 (28.7%)

Whole life

282 (31.8%)

127 (38.4%)

155 (27.2%)

Another slum in Port-au-Prince

253 (36.3%)

86 (33.9%)

167 (37.8%)

Elsewhere in Metropolitan Port-au-Prince

152 (26.6%)

54 (24.2%)

98 (28.0%)

205 (37.1%)

81 (41.9%)

124 (34.2%)

187 (21.7%)

67 (23.1%)

120 (20.7%)

Time in current neighborhood

[Among ever migrants] Previous residence

Elsewhere in Haiti or abroad
Away from current home for >1 month at a
time in past year
Cardiovascular disease risk factors
BMI
Underweight (< 18.5)

78 (9.3%)

34 (10.2%)

44 (8.7%)

Normal (18.5 - < 25)

462 (53.8%)

230 (69.2%)

232 (42.9%)

Overweight (25 - < 30)

232 (26.6%)

62 (17.0%)

170 (33.4%)

Obese (≥ 30)

100 (10.3%)

11 (3.6%)

89 (15.1%)

Central obesity

325 (35.8%)

21 (7.9%)

304 (55.4%)

Currently smokes cigarettes

68 (7.2%)

47 (11.8%)

21 (3.9%)

148 (17.7%)

109 (32.1%)

39 (7.4%)

2.1 (0.5-6.1)

2.4 (1.1-6.1)

1.9 (0.1-6.1)

1.6 (0.7-2.8)

1.6 (0.9-2.6)

1.6 (0.6-3.0)

606 (68.7%)

247 (69.1%)

359 (68.4%)

262 (33.2%)

95 (28.8%)

167 (36.3%)

517 (65.7%)

196 (61.3%)

321 (68.8%)

9.9 (6.7-12.0)

9.2 (5.7-11.7)

10.6 (7.3-12.3)

Health problem keeps from working

198 (20.2%)

59 (17.4%)

139 (22.3%)

Sought medical care in past year

304 (35.6%)

93 (26.8%)

211 (41.8%)

Did not receive needed care in past 6 months

235 (26.3%)

90 (25%)

145 (27.2%)

Consumes alcohol at least twice per week
Number of days/week drinks soda/sugary
drinks (median, IQR)
Mean number of days/week eats fresh
fruit/vegetables (median, IQR)
Eats at least one fried meal per day
Always or often adds salt or salty seasoning to
foods
Lives in a household with indoor cooking over
charcoal, wood, or fire
Psychological distress score (median, IQR)
Health status and healthcare access

Household environment
Number of HH members (median, IQR)

4.4 (2.9-6.0)

A HH owner owns dwelling

421 (46.8%)
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Table 2. Hypertension prevalence among slum community residents, by sex, age, and healthcare
access, Port-au-Prince, Haiti, 2016.
Crude
N
Overall*

886

Level 1**
Level 2**
Pre-hypertension**
Among those with measured
hypertension, type
Both systolic and diastolic

Overall N with
hypertension
(%)
179 (20.3%)

Men N with
hypertension
(%)
66 (22.3%)

Women N with
hypertension
(%)
113 (18.9%)

p-value
men vs
women
0.425

108 (12.6%)

44 (15.4%)

64 (10.7%)

0.333

53 (6.2%)

19 (6.2%)

34 (6.1%)

278 (27.5%)

115 (29.0%)

163 (26.4%)

69 (48.8%)

23 (45.2%)

46 (52.0%)

37 (20.5%)

16 (21.6%)

21 (19.5%)

55 (30.7%)

24 (33.1%)

31 (28.5%)

28.5%

29.6%

28.0%

161

Systolic only
Diastolic only
Overall, age standardized to WHO world
population
Age

0.667

18-24 years

258

21 (7.1%)

9 (13.5%)

12 (3.7%)

0.013

25-30 years

212

35 (16.8%)

13 (16.4%)

22 (17.1%)

0.908

31-44 years

261

61 (23.9%)

21 (16.9%)

40 (30.1%)

0.089

≥ 45 years

155

62 (43.6%)

23 (48.8%)

39 (39.6%)

0.262

300

72 (22.3%)

21 (26.6%)

51 (20.5%)

0.400

585

107 (19.2%)

45 (20.8%)

62 (17.9%)

0.458

232

62 (28.9%)

19 (26.4%)

43 (30.4%)

0.565

654

117 (17.3%)

47 (21.0%)

70 (14.6%)

0.094

Healthcare access
Sought medical care in past year
Yes
No
Did not receive needed care in past six
months
Yes
No
*Includes self-reported treatment from a clinic
**Includes only measured blood pressure

Table 3. Factors associated with prevalent hypertension among slum community residents, by sex,
Port-au-Prince, Haiti, 2016.
Men
Bivariate
N

OR

346

1.3 (1.1-1.4)

10

Women
aOR (N=333)

Bivariate
N

OR

aOR (N=531)

1.40 (1.2-1.6)

540

1.3 (1.2-1.4)

1.34 (1.2-1.5)

3.9 (0.8-19.2)

57

1.4 (0.9-2.4)

Sociodemographics
Age
5-year increase
Education
None
Primary

98

ref

186

ref

Secondary or higher

237

1.5 (0.9-2.6)

297

0.3 (0.2-0.6)

137

1.9 (1.1-3.2)

239

0.6 (0.4-1.0)

Time in current neighborhood
≤ 3 years

3.3 (1.8-6.2)

39

> 3 years

208

ref

ref

301

ref

Health status
Did not receive needed care in past 6 months
Yes

88

1.3 (0.8-2.3)

144

2.5 (1.5-4.4)

2.8 (1.3-5.9)

No

258

ref

396

ref

ref

346

1.0 (0.9-1.0)

538

1.1 (1.0-1.2)

Underweight (< 18.5)

34

0.3 (0.1-1.3)

0.3 (0.1-2.3)

44

0.7 (0.3-1.8)

Normal (18.5 - < 25)

228

ref

ref

230

ref

ref

Overweight (25 - < 30)

61

2.1 (1.1-4.0)

1.1 (0.5-2.3)

170

1.9 (1.1-3.4)

1.9 (1.1-3.3)

Obese (≥ 30)

11

1.5 (0.3-6.3)

1.0 (0.2-4.4)

87

4.3 (2.1-8.9)

5.7 (2.5-13.2)

Yes

21

6.2 (1.7-22.3)

302

2.8 (1.7-4.6)

No

321

ref

231

ref

45

1.0 (0.5-2.2)

21

0.6 (0.1-3.0)

301

ref

519

ref

39

0.4 (0.1-1.4)

501

ref

Kessler-6 psychological distress score
1-point increase
Individual risk factors
BMI
0.8 (0.3-2.5)

Central obesity

Tobacco use
Current smoker
Previous or never
smoker
Alcohol consumption

At least twice a week
106
0.8 (0.4-1.4)
Less than twice a
240
ref
week or never
Consumes fried food at least once a day
Yes

244

1.1 (0.5-2.4)

357

0.4 (0.3-0.8)

No

102

ref

181

ref

95

1.0 (0.4-2.2)

164

0.9 (0.6-1.5)

246

ref

374

ref

Indoor

210

1.0 (0.6-1.8)

337

0.7 (0.4-1.1)

Outdoor

126

ref

202

ref

1.0 (0.9-1.2)

540

0.9 (0.9-1.00)

540

1.2 (1.1-1.3)

Adds salty seasoning or sauce to foods
Always or often
Sometimes, rarely, or
never
Household environment
Cooking location

Number of household members
1-person increase

346

Waypoint hypertension prevalence (excluding self)
5 percentage point
346
1.4 (1.2-1.6)
increase

1.4 (1.2-1.7)

1.3 (1.2-1.4)
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Supplemental Table 1. Characteristics of slum community residents, by hypertension status, Port-auPrince, Haiti, 2016.
No hypertension*
(n=438)

Pre-hypertension*
(N=269)

Hypertension*
(N=179)

271 (61.8%)

156 (55.7%)

113 (54.8%)

Age (median, IQR)

25 (21-32)

30 (24-39)

39 (28-52)

Has no formal education

19 (2.8%)

30 (24-39)

22 (13.4%)

Migrated in ≤ 3 years ago
Percent adults with hypertension in waypoint
(median, IQR)
Health status and care-seeking

185 (39.5%)

112 (41.4%)

79 (39.9%)

15 (7-25)

18 (9-30)

30 (22-34)

Has a health problem prevents from working

95 (17.5%)

49 (18%)

52 (27.5%)

Psychological distress**

109 (23.7%)

72 (21.3%)

53 (29.8%)

148 (35.2%)

80 (32.4%)

72 (38.5%)

107 (22.5%)

63 (24.1%)

62 (36.7%)

153 (37.6%)

52 (25.5%)

54 (32.2%)

298 (70.4%)

184 (70.9%)

119 (61.1%)

1.6 (0.6-2.8)

1.7 (0.9-2.6)

1.5 (0.7-2.9)

Sociodemographic
Female

Sought medical care in past year
Did not receive needed medical care in past 6
months
Risk factors
Always or often adds salty seasoning or sauce to
food
Eats at least one fried meal per day
Average number of days per week eats fresh
fruit or vegetables (median, IQR)
Smokes cigarettes

38 (7.6%)

14 (6.3%)

14 (6.9%)

Consumes alcohol at least twice per week

71 (16.1%)

51 (21.6%)

23 (14.2%)

Obese

21 (3.7%)

33 (16.8%)

44 (18.4%)

BMI (median, IQR)

22 (19-25)

25 (21-28)

25 (22-28)

Waist circumference (median, IQR)

75 (70-82)

80 (75-87)

85 (77-95)

* Hypertension includes self-reported current treatment from a clinician, hence different Ns for no hypertension
and pre-hypertension than in table 2.
** Psychological distress defined as ≥13 points on the Kessler-6 scale
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CHAPTER 3: HYPERTENSION PATTERNS AMONG PATIENTS NEWLY
DIAGNOSED WIT HIV INITIATING ANTIRETROVIRAL TREATMENT, 20132017 (AIM 2)
ABSTRACT
Background: As life expectancy among people living with HIV (PLWH) increases with expanded access to
antiretroviral treatment (ART), the risk of non-communicable conditions such as cardiovascular disease
(CVD) increases. HIV and ART exposure may also independently raise the risk of CVD. I assessed the
prevalence and incidence of hypertension, a major CVD risk factor, as well as its status following onset,
among patients initiating ART in Haiti.
Methods: Longitudinal data for 671 individuals were used to estimate the prevalence, incidence rate,
and cumulative incidence of hypertension (defined using two consecutive blood pressure measurements
on separate days), along with trajectories of hypertensive status following hypertension onset. Factors
associated with incident hypertension were assessed via Fine-Gray subdistribution hazard models
accounting for death as a competing risk. The association between initial blood pressure level and
mortality was examined via Cox proportional hazard models.
Results: Overall, 11.6% of patients had prevalent hypertension at study enrollment, 35.9% of them stage
2. Incidence of hypertension was 10.8 per 100 person-years of follow-up. Among patients with prevalent
or incident hypertension, 43.5% still had hypertension on half or more of the follow-up measurements
over a median of 24 months of follow-up. Factors associated with incident hypertension included ages
40-54 and ≥ 55 years (adjusted subhazard ratio [aSHR] = 2.0, 95% confidence interval [CI]: 1.1-3.6, and
aSHR = 4.7, 95% CI: 2.2-10.1, respectively, compared to ages 30-39) and enrollment CD4 count ≤ 100
cells/µl (aSHR = 2.2, 95% CI: 1.01-4.8, compared to CD4 count 351-500 cells/µl). Initial systolic blood
pressure < 90 mmHg was associated with mortality, compared with systolic blood pressure between 90
and 139 mmHg.

42

Conclusions: There is substantial unmet need for hypertension treatment in this population receiving
HIV care and treatment. To protect life expectancy gains achieved via expanded ART access, it is critical
to extend prevention and treatment of hypertension to HIV care facilities, which provide repeated
opportunity for intervention.
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death and on the rise in low- and middleincome countries (LMICs), where three quarters of all non-communicable disease (NCD) deaths occur.
The World Health Organization (WHO) has set global goals targeting a 25% reduction of mortality from
CVD and hypertension, a major risk factor for CVD, by 2025.1 However, understanding of the burden of
NCDs and their determinants is limited in many LMICs, including Haiti. Recent cross-sectional data
suggest hypertension prevalence of approximately 20% among Port-au-Prince residents (29% agestandardized)2,3 and hypertensive heart disease is one of the fastest growing causes of death nationally.4
Haiti also has one of the highest stroke mortality rates in the Latin America/Caribbean region, and more
than twice that of the neighboring Dominican Republic.5
Prevention and treatment of hypertension and CVD is particularly complex in LMICs with high
background prevalence of HIV, such as Haiti, with 1.9% seroprevalence in metropolitan Port-au-Prince
overall, and as high as 4.5% among women ages 44-49.6 Owing to widespread antiretroviral treatment
(ART) access, people living with HIV (PLWH) in LMICs saw dramatic improvements in life expectancy,
becoming more susceptible to age-related conditions such as CVD.7 Furthermore, both HIV infection and
ART may increase the risk of CVD.7-10 Hypertension in particular may be induced by HIV and ART via
factors including chronic HIV-associated inflammation, immune suppression and reconstitution,
impairment in endothelial function and imbalance in the renin-angiotensin system, renal disease,
dyslipidemia, and lipodystrophy.11-14 Hypertension prevalence is higher among HIV-positive adults than
those without the infection,15-17 and related complications may also be more frequent, compared with
persons without HIV and with similar blood pressure levels.18
This study sought to estimate the prevalence and incidence of hypertension, and characterize
longitudinal hypertension status following hypertension onset, among persons with newly diagnosed
HIV initiating ART in Port-au-Prince, Haiti.
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METHODS
Study population and setting
This is a secondary analysis of data collected from participants who were enrolled in an unblinded,
randomized controlled trial of standard ART initiation versus same-day ART initiation at the GHESKIO
clinic in Port-au-Prince, Haiti (ClinicalTrials.gov number NCT01900080).19 GHESKIO (Haitian Group for the
Study of Kaposi’s Sarcoma and Opportunistic Infections) is a nongovernmental organization and the
largest provider of HIV and PMTCT services in Haiti.20,21
Eligibility
Participants were recruited from GHESKIO’s HIV voluntary counseling and testing center between
August 2013 and October 2015. Following HIV testing and posttest counseling, patients with a positive
result received same-day physician examination, CD4 count, WHO staging, and chest radiograph.
Patients were eligible for trial participation if they were infected with HIV-1, ≥ 18 years of age, and had
WHO stage 1 or 2 disease. Initially, participants also had to have a CD4 count ≤ 350 cells/µl, but the cutoff was raised in February 2014 to ≤ 500 cells/µl, consistent with revised national Haitian guidelines.22
Patients were excluded from the trial if they were already aware of their HIV diagnosis, had previously
received ART, were pregnant or breastfeeding, lived outside of the greater Port-au-Prince metropolitan
area, planned to transfer care during the study period, or failed to demonstrate ART readiness assessed
by a standard instrument.23 The trial was described in detail previously.19
To be included in this analysis, patients had to have at least two blood pressure measurements
recorded in the first four months of the study, and not have transferred out of HIV care at the GHESKIO
clinic during the first year of the study.
Procedures and data collection
Patients in the same-day ART initiation arm and in the standard ART initiation arm (with ART
initiation at three weeks after enrollment) received the same first-line therapy, a single pill combining
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tenofovir disoproxil fumarate, lamivudine, and efavirenz. In the first 5 weeks of the study, participants in
both arms had four study visits, though at slightly different schedules. In the standard arm, initial followup visits took place at 7, 14, 21 days, and 5 weeks after enrollment, while in the same-day arm, visits
took place at 3, 10, 17, and 24 days. Starting with week 7, visits in both arms were scheduled at a
monthly cadence. Following the first 12 months of the trial, continuing visits at the GHESKIO HIV clinic
would typically be scheduled every 2 to 6 months, per standard of care at the time. Per trial protocol
and subsequently the GHESKIO standard of care, visits included blood pressure measurements.
Definitions
Hypertension
Hypertension was defined as systolic blood pressure (SBP) ≥ 140mmHg or diastolic blood pressure
(DBP) ≥ 90 mmHg at two consecutive blood pressure measurements on separate days, per JNC-VII.24
Prescription of antihypertensive drugs by a medical professional was not included in the definition due
to the lack of prescription data. Date of hypertension onset was set to the date of the first of the two
measurements meeting the definition. Stage 2 hypertension was defined as SBP ≥ 160 mmHg or DBP ≥
100 mmHg, and stage 1 was defined as SBP between 140-159 mmHg, and DBP between 90-99 mmHg.
Other clinical variables
CD4 count at study enrollment was categorized into ≤ 100, 101-200, 201-350, and 351-500 cells/µl.
WHO disease stage at enrollment included 1 and 2. Body mass index (BMI) at enrollment was
categorized as underweight (BMI ≤ 18.5), normal (18.5-24.9), overweight (25.0-29.9), and obese (≥ 30).
Due to the low number of obese patients, for analysis the overweight and obese groups were combined.
Period of study enrollment was defined as before or after eligibility expansion to CD4 ≤ 500 cells/µl.
Sociodemographic variables
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On the day of enrollment, patients self-reported their education level (none, primary, secondary or
more), income (none, < 1 USD, 1-2 USD, or > 2 USD per day), and marital status (married or cohabitating,
previously married, or single).
Statistical analysis
Characteristics of participants and blood pressure measurements
Descriptive statistics were used to characterize sociodemographic and clinical characteristics of
participants overall and by period of enrollment, as well as the frequency and consistency of blood
pressure measurements over time. Median number and interquartile range (IQR) of blood pressure
measurements per patient, proportion of patients with first blood pressure measurement on the day of
enrollment, and time between blood pressure measurements were described.
Hypertension prevalence and incidence
Hypertension prevalence at enrollment was calculated using the first two blood pressure
measurements recorded within the first 4 months of the study. Among patients without prevalent
hypertension, incident hypertension was estimated as a rate per 100 person-years of follow-up.
Cumulative incidence was calculated via competing risks regression with Aalen-Johansen estimator,
treating death as a competing event. Patients were censored at the earlier of: 1) the date of database
close (July 6, 2017); or 2) 30 days after their last blood pressure measurement preceding a longer than
4-month gap in care. All prevalence and incidence measures were stratified by study period, sex, age at
enrollment, CD4 count category, and BMI. Cumulative incidence of hypertension at 6, 12, and 18 months
after enrollment was compared across strata using the Gray test.
Factors associated with incident hypertension within 12 months after enrollment
Fine-Gray subdistribution hazard models25 with robust standard errors were fitted to examine the
factors associated with incident hypertension, accounting for death as a competing risk. The
proportional hazards assumption was assessed by plotting of scaled Schoenfeld residuals. Because death
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dates were only available for the first 12 months of follow-up and due to violations of the proportional
hazards assumption after this timepoint, patients were censored at the earlier of: 1) 12 months after
their enrollment date; or 2) 30 days after their last blood pressure measurement preceding a longer
than 4-month gap in care.
Variables assessed in the models reflected previously reported risk factors for hypertension (sex,
age group, CD4 count category, and BMI category) and income level, as a proxy for socioeconomic
status.
Hypertensive status following hypertension onset
To approximate hypertension control and opportunity for medical intervention, for all patients who
met the hypertension definition and who had at least two blood pressure measurements afterwards,
hypertensive status of subsequent measurements was described and visualized in post-hoc analyses. All
subsequent measurements were included, without regard to time gaps between them. The number of
follow-up measurements was described, along with proportion which were not hypertensive, and
stratified by hypertension stage at onset (both hypertensive measurements stage 2, both stage 1, and
mixed: one stage 2, and one stage 1).
Association between initial blood pressure level and death in the first 12 months after enrollment
Cox proportional hazards models adjusted for sex and age were used to examine the association
between blood pressure level at enrollment (mean value of the two first measurements, categorized as
SBP ≥ 160, SBP between 140-159, SBP between 90-139, and SBP < 90 mmHg) and death in the first 12
months of follow-up. Patients were censored at the earlier of: 1) 12 months after their enrollment date;
or 2) 30 days after their last blood pressure measurement.
All analyses were completed in SAS 9.4 (Cary, NC).
Ethics
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The original clinical trial was approved by the institutional review boards at Partners Healthcare,
GHESKIO, Weill Cornell Medicine, and Florida International University. This analysis was approved by
institutional review boards at GHESKIO, Weill Cornell Medicine, and City University of New York.
RESULTS
Participant characteristics
Of the 821 patients screened for the original trial, 762 (92.8%) enrolled in the study. During the first
year of the study, 59 patients transferred out of GHESKIO, and 32 did not have any blood pressure
measurements recorded, resulting in the analytic sample for the current study of 671 patients (81.7% of
all individuals screened and 88.1% of those who enrolled).
Median age overall was 37 years, 50% of participants were men, and 58% had no more than
primary education. Across the study period, median CD4 count at enrollment was 247 cells/µl (IQR: 144345) and 16% of participants had a CD4 count ≤ 100 cells/µl. Fourteen percent of patients were
underweight and 16% were overweight or obese. (Table 1)
Blood pressure measurements
Overall, participants had a median of 18 blood pressure measurements on distinct days (IQR: 1223). Consistent with the trial protocol, the median number of measurements in the first 5 weeks of
follow-up was 5 (IQR: 4-5) in both study arms. The number of measurements in the first year of followup was equal across arms (median 14, IQR: 10-16), and the proportion of participants with the first
measurements on the day of enrollment was similar (96-97%). The median time between individual
blood pressure measurements was 4 weeks in both arms. (Supplemental Table 1)
Hypertension prevalence and incidence
The prevalence of hypertension at enrollment was 11.6% (96% confidence interval [CI]: 9.3-14.3%).
Prevalence increased with participant age, reaching 26.1% (95% CI: 14.3-41.1%) among participants
enrolling at the age of ≥ 55. (Table 2, Figure 1) Among 78 patients with prevalent hypertension, 28
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(35.9%) had stage 1 hypertension at both initial measurements, another 28 (35.9%) had stage 2 at both
measurements, and 22 (28.2%) had one of each.
Among participants free of hypertension at enrollment, the incidence was 10.8 (95% CI: 9.0-12.9)
per 100 person-years of follow-up, with a cumulative incidence of 18.5% at 18 months after enrollment.
Cumulative incidence differed appreciably across age and BMI categories (p < 0.001 and p = 0.009,
respectively): at 18 months, it was 31.6% among overweight and obese patients, compared with 18.5%
among normal-weight, and 7.4% among underweight patients.
Factors associated with incident hypertension in the 12 months after enrollment
In multivariable analysis, the risk of incident hypertension was higher among patients ages ≥55
years (adjusted subhazard ratio [aSHR] = 4.7, 95% CI: 2.2-10.1) and ages 40-54 years (aSHR = 2.0, 95% CI:
1.1-3.6), compared to those ages 30-39. Patients with CD4 counts ≤ 100 cells/µl also had a higher risk of
incident hypertension (aSHR = 2.2, 95% CI: 1.01-4.8), compared to patients with CD4 counts between
351-500 cells/µl. (Table 3)
Hypertensive status following hypertension onset
Among 170 patients who met the definition of prevalent or incident hypertension, 161 (94.7%) had
at least 2 more blood pressure measurements afterwards and were included in this subanalysis. Among
these patients, the median number of subsequent measurements was 14 (IQR: 9-18), over a median of
24.4 months of follow-up (median: 16.3-32.0 months). Of the 161 patients, 69 (42.9%) had hypertension
stage 1 at onset, 39 (24.2%) – stage 2, and 53 (32.9%) – mixed stages. Of patients with initial stage 1
hypertension, 11.6% (8/69) developed stage 2 during follow-up, as did 35.9% (19/53) of those with
initial mixed stage. (Figure 2)
Among the 161 patients, 70 (43.5%) had hypertension at half or more of the follow-up
measurements, ranging from 20.3% (14/69) of patients with initial stage 1 hypertension to 47.2%
(25/53) of those with initial mixed stage and 79.5% (31/39) of those with initial stage 2. Eighteen
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patients had hypertension at each recorded subsequent measurement (median 15 measurements, IQR:
9-16).
Within all three initial hypertension stage groups, patients who did not have hypertension at half or
more of the follow-up measurements were appreciably younger than patients who did (median ages 41
versus 44 among those with initial stage 1, 41 versus 52 – mixed stage, and 36 versus 48 – stage 2).
Association between initial blood pressure level and death
Over the first year of follow-up, 23 deaths were recorded. Controlling for age and sex, patients with
initial SBP < 90 mmHg had 3.7 times the risk of death (95% CI: 1.1-12.6) as patients with initial SBP
between 90-139 mmHg. No association was observed between SBP between 140-159 or ≥ 160 mmHg
and death during the first year of follow-up.
DISCUSSION
The study found that 11.6% of newly diagnosed patients initiating ART at a Port-au-Prince HIV clinic
had prevalent hypertension, with cumulative incidence among those hypertension-free at enrollment
reaching 18.5% within 18 months after. While hypertension treatment status was unknown following
hypertension onset, hypertensive status often persisted for months or years after onset, especially
among patients with stage 2 hypertension at onset.
At 11.6%, the prevalence of hypertension at enrollment in this study is over twice as high as the
5.3% prevalence among ART-naïve, stage I-III GHESKIO patients with CD4 counts between 200 and 350
cells/µl, and with the median age of 39 years, in a 2005-2008 trial of early versus deferred ART
initiation.26 Incidence rate in this study was three times as high: 10.8 per 100 person-years of follow-up,
compared to 3.4 in the 2005-2008 GHESKIO study. Altogether, this comparison of two GHESKIO cohorts
with similar median age and median enrollment CD4 count might suggest an increasing secular trend in
hypertension in this population.
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While the incidence was similar to the 11.2 per 100 person-years among adults who initiated ART
between 2010-2012 in Uganda,27 it was substantially higher than rates reported in cohorts combining
ART-naïve and ART-exposed PLWH in high-income countries: 3.0 per 100 person-years in Norway,28 3.4
in the D:A:D cohort including patients from across Europe, Australia, and the United States,29 and 6.4 in
the United States.30 In the present study, similar to the results from Uganda, the incidence of
hypertension among even the youngest patients aged 18-29 years (7.4 and 9.2 per 100 person-years,
respectively) was higher than the overall estimates from high-income countries.
Patients with CD4 counts ≤100 cells/ µl had highest hypertension incidence and were at higher risk
of incident hypertension in adjusted analysis. Although no data were available on post-enrollment CD4
count trajectory, this finding may be consistent with prior research that reported associations between
nadir CD4 count and hypertension, potentially induced by chronic immune activation and inflammation.
In a study in Tanzania, hypertension prevalence was highest among patients whose previously low CD4
counts were most reconstituted while on ART.17 Low nadir CD4 count was also found to be a strong risk
factor for incident hypertension among patients on ART in Uganda27 and for sustained hypertension in
Norway.31 Additionally, particularly high prevalence and incidence of hypertension was observed among
patients 55 years of age or older, as well as overweight and obese patients, consistent with established
risk factors in the general population.
Many of the patients with hypertension continued to have hypertensive blood pressure levels for
months or years after hypertension onset, especially patients with stage 2 hypertension at onset. While
no treatment data are available to examine the extent to which this represents unsuccessful treatment
versus lack thereof, the observed patterns suggest potentially missed opportunities to engage patients
in treatment and reduce the risk of future CVD. While NCD care and prevention are often concentrated
in higher-level medical facilities in LMICs,32 HIV patients’ regular lifelong engagement with lower-level

52

facilities provides an opportunity to extend prevention and treatment for conditions such as
hypertension to this population at high risk of CVD.
At the same time, the apparent lack of consistent hypertensive measurements following onset
among some patients, largely those with initial stage 1 hypertension, suggests that measurement error
and/or “white coat hypertension” might be driving an overestimate of hypertension in this population.
However, since “white coat hypertension” has been linked to increased cardiovascular risk33 (though not
conclusively), patients with such blood pressure patterns might also merit closer attention with respect
to primary and/or secondary prevention, particularly if they have other known risk factors for the
condition, such as older age. Patients whose blood pressure mostly returned to normotensive tended to
be substantially younger than those who largely maintained hypertensive levels, suggesting that the 2day hypertension definition may have low specificity among young people in this setting.
The association between low initial SBP and mortality within the first year of follow-up was similar
to that observed in the previous GHESKIO study26 and in a large analysis of HIV-positive adults in
Kenya.34 The question is particularly relevant for HIV patients due to the association of certain
opportunistic infections such as histoplasmosis with lower blood pressure levels.35 In addition to
concomitant infections, adrenal insufficiency, autonomic dysfunction, bacterial translocation, and
advanced HIV disease itself have been linked with low blood pressure among HIV patients, pointing to
the importance of further study of the interrelated factors that may be increasing the risk of mortality in
this population.34 There was no evidence for the link between high initial blood pressure and mortality,
previously documented in general36-41 and in HIV-positive populations.26,34 However, this study may not
have had enough statistical power to detect differences in mortality, as death data were only available
for the first year of follow-up, resulting in a low number of events.
Altogether, the findings highlight the potential for growth in the hypertension and NCD burden in
Haiti, as well as unmet need for prevention, screening, and quality treatment services. HIV programs,
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adept at providing care for this initially minimally symptomatic condition that requires patient selfmanagement, similar to hypertension, may be well suited to leverage existing tools to offer NCD
services. Despite gaps in readiness to provide NCD care,42,43 integrated HIV and NCD services are
increasingly introduced, with mixed success.44,45 At GHESKIO, an integrated care pilot reported high
retention and moderate hypertension control over a six-month period.46 Hypertension screening and
management were incorporated into routine HIV visits, limiting the need for additional staffing and
minimizing the number of patient visits. By relying on low-cost point-of-care proteinuria screening as
marker for kidney function, and drugs from the WHO list of essential medicines, the program sought to
maximize affordability and accessibility, a critical consideration in the absence of a dedicated funding
stream for NCD care similar to President's Emergency Plan for AIDS Relief (PEPFAR) for HIV.
Major strengths of the study were the availability of multiple and frequent blood pressure
measurements at and up to 4 years after ART initiation, and the application of the 2-day hypertension
definition recommended by JNC-VII.24
Among limitations, prevalence and incidence are likely slightly underestimated because of
unavailability of hypertension treatment data. At the same time, because death data were only available
for the first year of follow-up, cumulative incidence calculations likely misclassify some subsequent,
unknown deaths as loss to follow-up, slightly overestimating cumulative incidence of hypertension at
timepoints past 12 months after enrollment. There were also no data available for a number of key risk
factors for high blood pressure, such as diet, smoking, diabetes, chronic kidney disease, family history,
and exposure to stress. While all patients initiated ART around the same time (day 0 or day 21), data on
subsequent ART receipt, gaps, or regimens were not available for analysis, precluding the assessment of
longitudinal exposure to ART as a possible correlate of incident hypertension.
Finally, despite the high participation rate in the original clinical trial, findings have limited
generalizability. Participants were ART-ready PLWH with CD4 counts ≤500 cells/µl, and may not be
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representative of patients increasingly entering care with higher CD4 counts, as LMICs expand ART
eligibility and access to care.
CONCLUSION
In a cohort of newly diagnosed patients initiating ART in Haiti, high levels of prevalent and incident
hypertension were observed, along with apparent failure to control blood pressure among a significant
subset of patients with hypertension, suggesting substantial unmet need for hypertension treatment in
this service-engaged population. In order to protect life expectancy gains among PLWH in LMICs
achieved via expanded ART access, it is critical to extend prevention and treatment of NCDs and their
risk factors such as hypertension in this population that is at increased risk of CVD.
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TABLES AND FIGURES
Figure 1. Cumulative incidence of hypertension among newly diagnosed with HIV patients initiating
ART and free of hypertension at study enrollment, by a) study period; b) age; c) CD4 count at
enrollment; d) body mass index, Port-au-Prince, Haiti, 2013-2017.

Circles represent incident cases of hypertension. Lines were smoothed using penalized b-splines of degree 2.

58

Figure 2. Hypertensive status of blood pressure measurements starting with hypertension onset, by
hypertension level at onset, among newly diagnosed with HIV patients initiating ART, Port-au-Prince,
Haiti, 2013-2017.

Table 1. Baseline characteristics of newly diagnosed with HIV patients initiating ART, by period of
study enrollment, Port-au-Prince, Haiti, 2013-2017.

Characteristic

Overall (N=671)

Period of enrollment
Before eligibility
After eligibility
expansion to CD4 ≤ 500 expansion to CD4 ≤ 500
(N = 130)
(N = 541)

Sociodemographic
Sex
Female
Male

335 (50%)

65 (50%)

270 (50%)

336 (50%)

65 (50%)

271 (50%)

37 (30, 45)

39 (31, 44)

37 (30, 46)

18-29 years

157 (23%)

27 (21%)

130 (24%)

30-39 years

222 (33%)

40 (31%)

182 (34%)

40-54 years

246 (37%)

53 (41%)

193 (36%)

≥ 55 years

46 (7%)

10 (8%)

36 (7%)

None

177 (26%)

27 (21%)

150 (28%)

Primary

211 (31%)

48 (37%)

163 (30%)

Age (years): Median (IQR)
Age category

Education level

59

Secondary or more

283 (42%)

55 (42%)

228 (42%)

None

319 (48%)

61 (47%)

258 (48%)

< 1 USD per day

132 (20%)

25 (19%)

107 (20%)

1-2 USD per day

43 (6%)

11 (8%)

> 2 USD per day

177 (26%)

33 (25%)

144 (27%)

Married or cohabitating

409 (61%)

85 (65%)

324 (60%)

Previously married

123 (18%)

24 (18%)

99 (18%)

Single

139 (21%)

21 (16%)

118 (22%)

247 (144, 345)

224 (135, 278)

261 (150, 372)

≤100 cells/µl

107 (16%)

18 (14%)

89 (16%)

101-200 cells/µl

146 (22%)

41 (32%)

105 (19%)

201-350 cells/µl

263 (39%)

71 (55%)

192 (35%)

351-500 cells/µl

155 (23%)

.

155 (29%)

203 (30%)

25 (19%)

178 (33%)

468 (70%)

105 (81%)

363 (67%)

21.3 (19.5, 23.6)

21.0 (19.3, 23.5)

21.3 (19.6, 23.6)

Underweight (BMI < 18.5)

93 (14%)

17 (13%)

76 (14%)

Normal (BMI 18.5-24.9)

465 (69%)

86 (66%)

379 (70%)

Overweight (BMI 25.0-29.9)

96 (14%)

22 (17%)

74 (14%)

Obese (BMI ≥ 30.0)

14 (2%)

5 (4%)

9 (2%)

Unknown

3 (1%)

0 (0%)

3 (1%)

Standard of care

337 (50%)

66 (51%)

271 (50%)

Same-day ART initiation

334 (50%)

64 (49%)

270 (50%)

Income

32 6%)

Marital status

Clinical
CD4 count at enrollment (cells/µl): Median (IQR)
CD4 count category

WHO status at enrollment
1
2
Body mass index (BMI) at enrollment: Median
(IQR)
Body mass index (BMI) at enrollment

Study arm
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Table 2. Prevalence, incidence rate, and cumulative incidence of hypertension among newly diagnosed with HIV patients initiating ART, Portau-Prince, Haiti, 2013-2017.
At 6 months

At 12 months

At 18 months

593

Incidence / 100
person-years of
follow-up
10.8 (9.0-12.9)

10.8 (8.5 - 13.8)

14.0 (11.3 - 17.4)

18.5 (15.0 - 22.8)

6.2 (2.7 - 11.8)

122

11.3 (8.1-15.7)

8.3 (4.6 - 15.1)

13.3 (8.3 - 21.5)

22.7 (15.7 - 32.8)

541

12.9 (10.2 - 16.1)

471

10.6 (8.6-13.1)

11.5 (8.9 – 15.0)

14.1 (11.1 – 18.0)

16.7 (12.9 - 21.5)

Female

335

11.9 (8.7 - 15.9)

295

10.7 (8.3-13.7)

10 (7.0 - 14.3)

11.9 (8.6 - 16.5)

18.7 (13.7 - 25.4)

Male

336

11.3 (8.1 - 15.2)

298

10.9 (8.4-14.0)

11.7 (8.4 - 16.3)

16.2 (12.2 - 21.6)

20.1 (14.9 - 27.2)

N

Prevalence
at enrollment

N

671

11.6 (9.3 - 14.3)

Before eligibility expansion to CD4 ≤ 500

130

After eligibility expansion to CD4 ≤ 500

Patient subgroup
Overall

Cumulative incidence

pvalue*

Study period
0.662

Sex
0.816

Age at enrollment
18-29

157

0.6 (0 - 3.5)

156

7.4 (4.8-11.3)

4.6 (2.2 - 9.6)

5.8 (2.9 - 11.6)

16.3 (9.4 - 28.3)

30-39

222

9.5 (6.0 - 14.1)

201

7.6 (5.3-10.8)

8.8 (5.5 - 14.2)

9.6 (6.1 - 15.3)

15.6 (9.7 - 25.1)

40-54

246

17.9 (13.3 - 23.3)

202

13.5 (10.3-17.5)

14.1 (10.0 - 20.1)

20.7 (15.5 - 27.7)

21.7 (16.2 - 28.9)

≥ 55

46

26.1 (14.3 - 41.1)

34

36.3 (23.6-51.9)

29.9 (17.7 - 50.3)

40 (26.1 - 61.2)

56.9 (33.7 - 96.2)

≤ 100 cells/µl

107

8.4 (3.9 - 15.4)

98

14.6 (10.0-20.9)

18.2 (11.8 - 28.1)

21.3 (14.2 - 32)

23.5 (15.7 - 35.2)

101-200 cells/µl

146

7.5 (3.8 - 13.1)

135

10.0 (6.8-14.5)

10.4 (6.2 - 17.4)

14.4 (9.2 - 22.5)

18.0 (11.5 - 27.9)

201-350 cells/µl

263

13.7 (9.8 - 18.4)

227

10.0 (7.4-13.4)

10.5 (7.1 - 15.7)

14.5 (10.2 - 20.5)

21.6 (15.5 - 30.2)

351-500 cells/µl

155

14.2 (9.1 - 20.7)

133

10.2 (6.7-15.2)

7.2 (3.8 - 13.7)

9.8 (5.4 - 17.5)

13.0 (6.9 - 24.5)

Underweight (BMI < 18.5)

93

5.4 (1.8 - 12.1)

88

6.6 (3.5-12.1)

5.7 (2.4 - 13.3)

7.4 (3.4 - 16.1)

7.4 (3.4 - 16.1)

Normal (BMI 18.5-24.9)

465

10.8 (8.1 - 13.9)

415

10.5 (8.4-13.0)

10.4 (7.7 - 13.9)

13.9 (10.7 - 18.1)

18.5 (14.4 – 24.0)

Overweight or obese (BMI ≥ 25.0)
110
20.9 (13.7 - 29.7)
87
16.3 (11.2-23.1)
18 (11.4 - 28.6)
Incidence and cumulative incidence denominators include all patients who did not have prevalent hypertension.
* p-values are from the Gray test, comparing cumulative incidence curves across strata

22.6 (14.9 - 34.1)

31.6 (21.6 - 46.3)

<0.001

CD4 count category

0.392

Body mass index (BMI) at enrollment
0.009
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Table 3. Factors associated with incident hypertension in the first 12 months after study enrollment
among newly diagnosed with HIV patients initiating ART, Port-au-Prince, Haiti, 2013-2017.
Bivariate
Characteristic

Multivariable (N = 590)

N

SHR (95% CI)

p-value

aSHR (95% CI)

p-value

Female

295

ref

0.241

ref

0.759

Male

298

1.3 (0.8-2.1)

18-29 years

156

0.5 (0.2-1.2)

30-39 years

201

ref

ref

40-54 years

202

2.1 (1.2-3.8)

2.0 (1.1-3.6)

≥ 55 years

34

4.4 (2.1-9.3)

4.7 (2.2-10.1)

Sociodemographic
Sex
1.1 (0.6-1.8)

Age group
<0.001

0.6 (0.2-1.5)

<0.001

Income
None

161

ref

< 1 USD per day

277

1.8 (0.9-3.5)

0.060

1.2 (0.6-2.4)

ref

0.634

1-2 USD per day

117

1.9 (0.9-4.0)

1.2 (0.5-2.7)

> 2 USD per day

38

3.2 (1.4-7.4)

1.9 (0.7-4.7)

≤ 100 cells/µl

98

2.2 (1.03-4.7)

101-200 cells/µl

135

1.4 (0.7-3.1)

1.3 (0.6-2.9)

201-350 cells/µl

227

1.4 (0.7-2.8)

1.2 (0.6-2.5)

351-500 cells/µl

133

ref

ref

Underweight (BMI < 18.5)

88

0.5 (0.2-1.2)

Normal (BMI 18.5-24.9)

415

ref

ref

Overweight or obese (BMI ≥ 25.0)

87

1.7 (1.0-2.9)

1.6 (0.9-2.9)

Clinical
CD4 count category
0.214

2.2 (1.01-4.8)

0.201

Body mass index at enrollment
0.025

0.5 (0.2-1.3)

0.068

Supplemental table 1. Characteristics of blood pressure measurements among newly diagnosed with
HIV patients initiating ART, Port-au-Prince, Haiti, 2013-2017.
Overall
Total number of BP measurements available*
Median (IQR)
18 (12 - 23)
Total number of BP measurements in the first year of follow-up
Median (IQR)
14 (10 - 16)
Total number of BP measurements in the first 5 weeks after enrollment
Median (IQR)
5 (4 - 5)
Total number of BP measurements until outcome**
Median (IQR)
12 (5- 18)
Time from HIV testing /study enrollment to first BP measurement
Same day
647 (96%)
Not same day
24 (4%)
Time between BP measurements (weeks)

Study arm
Standard ART
Same-day ART
(N=337)
(N=334)
18 (11 - 23)

19 (13 -23)

14 (10 - 16)

14 (10-16)

5 (4 - 5)

5 (4 - 5)

11 (5 - 18)

12 (5 - 18)

321 (96%)
13 (4%)

326 (97%)
11 (3%)
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Median (IQR) of patient-level medians
4.0 (3.4 - 4.4)
4.0 (3.1 - 4.4)
4.0 (3.6 - 4.3)
Within ≤2 weeks of prior
3,107 (28%)
1,553 (28%)
1,554 (27%)
Within >2 - ≤4 weeks of prior
2,618 (23%)
1,250 (23%)
1,368 (24%)
Within >4 - ≤8 weeks of prior
2,918 (26%)
1,399 (26%)
1,519 (27%)
Within >8 weeks of prior
2,514 (23%)
1,226 (23%)
1,288 (22%)
BP = blood pressure
Measurements only on distinct days
*Includes all measurements, even those after gaps if patient returned, or after hypertension onset
**Outcome is date of hypertension onset among those with the outcome of hypertension, date of death among
those with death, date of start of the first 4-month gap among those censored due to data gap, and date of study
end among the rest.
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CHAPTER 4: BLOOD PRESSURE PATTERNS AND HYPERTENSION
AMONG HIV-POSITIVE PREGNANT WOMEN, 2007-2016 (AIM 3)
ABSTRACT
Background: Hypertensive disorders of pregnancy are a key driver of mortality and morbidity among
Haitian women. HIV-infection and treatment may affect hypertension and cardiovascular disease risk in
pregnant women.
Methods: I described blood pressure and hypertension patterns among 2,306 pregnancies to 1,965
unique women enrolled in a prevention of maternal-to-child transmission (PMTCT) program in Port-auPrince, Haiti, between 2007 and 2016. Hypertension was defined using two consecutive blood pressure
measurements on separate days. Using latent class modeling, I assessed trajectories of mean arterial
pressure (MAP) during pregnancy and identified factors associated with higher MAP trajectories via
multinomial ordinal logistic regression.
Results: Between 2007-2009 and 2013-2016, chronic and gestational hypertension increased from 1.1%
to 3.5% (p = 0.003) and from 2.3% to 6.9% (p < 0.001), respectively. Prevalent hypertension increased
from 1.3% to 3.8% (p = 0.005), while incidence increased from 5.0 to 16.1 per 100 person-years (p
<0.001). Longer duration of antiretroviral therapy (ART) exposure had a strong, dose-response
association with higher MAP trajectory: pregnancies with > 1 to 3 years or > 3 years of prior ART
exposure had 2.7 times the adjusted odds of higher trajectory (95% CIs: 1.7-4.3 and 1.6-4.5,
respectively) as pregnancies with no prior ART exposure. Older age was also associated with greater
odds of higher trajectory (aOR for age > 40 versus 20-40 years = 2.5, 95% CI: 1.3-4.7), as were
pregnancies which were the women’s first in the program (aOR for first vs second pregnancy = 1.5, 95%
CI: 1.02-2.1), and higher weight at PMTCT entry (aOR = 1.03 for each kilogram increase, 95% CI: 1.011.04).
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Conclusions: A substantial and increasing prevalence and incidence of hypertension highlights a need for
treatment prior to PMTCT entry and during PMTCT follow-up. In a population with limited access to
chronic disease care, and where many deliveries occur outside of a clinical setting, the period of PMTCT
follow-up represents an opportunity to diagnose and initiate management of chronic and gestational
hypertension alike.
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INTRODUCTION
Haiti’s maternal mortality rate is the highest in the Western Hemisphere with an estimated 521
deaths for every 100,000 live births, almost 10 times as high as in the neighboring Dominical Republic.1
Although 91% of Haitian women report receiving some form of prenatal care for their most recent
pregnancy, fewer than four in ten births take place in a healthcare facility, and two thirds of women get
no postnatal care at all.2
Hypertensive disorders of pregnancy are a major cause of maternal and perinatal morbidity and
mortality, affecting about 10% of pregnancies worldwide.3 In Latin America and the Caribbean, these
conditions are estimated to be responsible for over a quarter of maternal deaths4 and have been
documented at substantial rates among HIV-positive pregnant women.5 In Haiti, rates of antepartum
eclampsia and pre-eclampsia as high as 18% have been documented in rural hospitals,6-8 along with
substantial presence of postpartum eclampsia among women delivering in9 or outside of a clinical
setting.6 Strong associations between hypertensive disorders of pregnancy and adverse outcomes such
as low birth weight, stillbirth, and maternal death, have also been documented in Haiti.8 Important risk
factors for pre-eclampsia include advanced maternal age, obesity, primiparity, multiple pregnancy, and
history of elevated blood pressure. Additionally, elevated mean arterial pressure (MAP) in pregnancy
has been associated with increased risk of pre-eclampsia.10-12
Overweight and obesity are common among Haitian women of reproductive age, as is background
hypertension.2,13 An additional complication to pregnancies in this population is the high prevalence of
HIV, increasing steadily from 0.3% among women ages 15 to 19, to 4.5% among those ages 44 to 49, or
2.3% overall.2 HIV and antiretroviral (ARV) medications may induce hypertension via factors including
chronic HIV-associated inflammation, immune suppression and reconstitution, impairment in
endothelial function and imbalance in the renin-angiotensin system, renal disease, dyslipidemia, and
lipodystrophy.14-17 Hypertension prevalence is higher among HIV-positive adults than those without the
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infection,18-20 and related complications may also be more frequent, compared with persons without HIV
and with similar blood pressure levels.21 Among pregnant women specifically, findings on the association
between HIV infection and ARV history, and hypertensive disorders of pregnancy, have been mixed.5,22-34
Maternal health remains a key area of morbidity and mortality for Haitian women, against a
backdrop of sustained background prevalence of HIV. This study sought to describe blood pressure and
hypertension patterns among HIV-positive pregnant women enrolled in a prevention of mother-to-child
transmission (PMTCT) program in Port-au-Prince, Haiti.
METHODS
Study population and setting
Participants were pregnant HIV-positive women enrolled in the PMTCT program at the GHESKIO
clinic in Port-au-Prince, Haiti. GHESKIO (Haitian Group for the Study of Kaposi’s Sarcoma and
Opportunistic Infections) is a nongovernmental organization and the largest provider of HIV and PMTCT
services in Haiti.35,36 The clinic provides HIV testing to over 4,000 pregnant women every year, with 9%
of the women testing HIV positive. Upon entry in the PMTCT program, women received a physical
examination, World Health Organization (WHO) staging, a CD4 count test, tetanus vaccination, and
antenatal assessment, including collection of sociodemographic data.37 Follow-up appointments were
scheduled every 4 weeks until 8 months of gestation, and weekly thereafter. During these visits, blood
pressure measurement was recommended and medication refills were dispensed (ferrous sulphate, folic
acid, and ARV medications, if indicated). The policies guiding HIV treatment of pregnant women
followed WHO and national guidelines. (Supplemental table 1)
Retrospective clinical and laboratory data were abstracted from GHESKIO electronic medical
records for pregnancies of women who entered the PMTCT program between January 1st, 2007 and
December 28th, 2016.
Eligibility
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To be included in the analysis, a pregnancy had to be confirmed by labs and ultrasound, have a
known confirmed or estimated delivery date, ≥12 weeks PMTCT follow-up between entry (first PMTCT
visit) and delivery date, and ≥3 blood pressure measurements on separate days during PMTCT follow-up.
Excluded were pregnancies known to have ended in an abortion, stillbirth, or maternal death.
Definitions
Hypertension
Almost all blood pressure measurements had been recorded in cmHg, i.e., a reading of 12/8 cmHg
could represent anything from 120/80 mmHg to 129/89 mmHg. Therefore, for this analysis, a ”5” was
added to all readings (with 12/8 cmHg becoming 125/85 mmHg, for example).
Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure
(DBP) ≥ 90 mmHg at two consecutive measurements on separate days,38 which is referred to as the
“two-day definition”. Prescription of antihypertensive drugs by a medical professional was not included
due to the lack of prescription data. Hypertension was considered as stage 2 with SBP ≥ 160 mmHg or
DBP ≥ 100 mmHg at two consecutive measurements.
Hypertension was considered prevalent if the first two measurements following PMTCT entry met
the definition. Among patients without prevalent hypertension, hypertension was considered incident if
any two consecutive measurements met the definition. Date of hypertension onset was set to the date
of the first of the two measurements meeting the definition.
All instances of prevalent or incident hypertension were categorized as chronic (if the onset was ≤
20 weeks gestation) or gestational (if the onset was > 20 weeks gestation).39 No data were available on
urine protein or labs such as platelet count or transaminase, which would help differentiate between
gestational hypertension and likely pre-eclampsia.
Additionally, to enhance comparability with a wider range of published research, hypertension
definitions were applied using a single measurement criterion (referred to as “single-day definition”).
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Other clinical variables
For each pregnancy, multiple status, pregnancy’s sequence at GHESKIO, and gestational age at
PMTCT entry were recorded. Gestational age was based largely on the date of the last reported
menstrual period. To represent the woman’s HIV exposure and clinical status, time between the first
known HIV diagnosis and PMTCT entry, WHO stage, and CD4 count at entry (within +/- 30 days) were
described. ARV exposure was coded as none until delivery, mono- or bi-regimen during pregnancy, and
four levels of triple-ARV antiretroviral therapy (ART), based on the timing of its initiation: at PMTCT
entry, up to a year before entry, 1-3 years before entry, or more than 3 years before entry.
Sociodemographic variables
For each pregnancy, the woman’s age at PMTCT entry was calculated. Additionally, the woman’s
education level, income, marital status, residence area, and whether she resided in a neighborhood with
a high slum concentration (proxies for socioeconomic status) were collected at PMTCT entry for the
woman’s first pregnancy at GHESKIO.
Statistical analysis
Characteristics of pregnancies and hypertension measures
Descriptive statistics were used to characterize pregnancies included in and excluded from the
analysis, and the proportion of pregnancies with chronic, gestational, prevalent, and stage 2
hypertension, overall and by program period. Among patients without prevalent hypertension,
incidence rate of hypertension was calculated per 100 person-years of follow-up. All hypertension
measures were calculated using the two-day and the single-day definitions.
Additionally, for measures calculated using the two-day definition, time trend across the three
entry periods was tested using logistic regression (for proportions) and Cox proportional hazards models
(for incidence rates), all of which accounted for the clustering of pregnancies within women.
Characteristics of blood pressure measurements
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To assess the consistency of measurements over time, descriptive statistics such as medians and
proportions were used. Additionally, the distribution of measurements was assessed visually through a
heatmap representing the proportion of measurements in each period that fell within each week
preceding delivery.
Trajectories of mean arterial pressure (MAP)
To describe blood pressure patterns and identify pregnancies at potentially increased risk of preeclampsia, previously linked to MAP,10-12 trajectory of MAP ([SBP + 2 x DBP] / 3) was modeled. Latent
class models identified subgroups of pregnancies sharing similar underlying trajectory. The approach
assumes that the population is made up of multiple trajectory groups and uses a semiparametric, groupbased modeling strategy which takes advantage of traditional methods for analyzing developmental
trajectories – hierarchical modeling and latent growth curve modeling. Longitudinal MAP values were
thus modeled as a discrete mixture of multiple trajectories via maximum likelihood.40-42
Models with different numbers and forms of potential trajectories were tested, with model fit
assessment via the Bayesian Information Criterion (BIC). A censored normal model for continuous
outcomes was used, with time remaining until delivery, in weeks, as the scale for time period. Starting
with all trajectory classes in quadratic form, models with 5 classes were examined, then the BIC was
compared to that of models with 4, 3, 2, and 1 class. As the model with 5 classes fit best, its fit was
compared across different functional forms. The final model had 2 classes with up to quadratic order
terms and 3 classes with up to cubic order terms. Each pregnancy was assigned to the trajectory group
for which it had the greatest posterior predictive probability. Finally, the resulting trajectories were
qualitatively examined and assigned names representing the observed visual patterns.
Factors associated with higher MAP trajectories
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To assess characteristics associated with higher MAP trajectories, a multinomial ordinal logistic
regression model accounting for clustering of pregnancies within women was developed.43 The bottom
three trajectories, roughly corresponding to normal MAP, were grouped together for analysis.
Variables considered for inclusion in the model were known risk factors for gestational
hypertension and pre-eclampsia such as age group (with a category for advanced maternal age defined
as over 40 years old) and pregnancy sequence at GHESKIO (as a proxy for parity),39,44 as well as factors
related to pregnant woman’s HIV disease status (CD4 count and WHO stage at PMTCT entry, ART
exposure), and education (as a proxy for socioeconomic status). Multiple pregnancy status was not
included because there were no multiple pregnancies in the highest MAP trajectory.
Variables were included in multivariable analysis if they were considered risk factors for gestational
hypertension and pre-eclampsia (age group, pregnancy sequence at GHESKIO, weight) or if they had pvalues <0.2 in bivariate analysis, and were not highly correlated with other variables in the multivariable
model. Weight in kilograms, rather than BMI, was used in analyses, due to its much higher completeness
across all three time periods.
All analyses were completed in SAS 9.4 (Cary, NC).
Ethics
This analysis of routinely collected de-identified data was approved by the Ethics Board at GHESKIO
and the institutional review boards at Weill Cornell Medicine and City University of New York.
RESULTS
Cohort characteristics
Altogether, 2,306 pregnancies among 1,965 unique women met the inclusion criteria. (Figure 1)
The median age at PMTCT entry was 29 years (IQR: 25-34), with 8% of women younger than 20 or older
than 40. There was no appreciable change in age distribution over time. Over half (55%) of pregnancies
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were to women who had no income at the time of their first pregnancy at GHESKIO. Almost all (90%)
pregnancies were among women who resided in metropolitan Port-au-Prince area. (Table 1)
Median gestational age at PMTCT entry was 15 weeks (IQR: 10-20), 2% of pregnancies were
multiple, and 71% were the woman’s first pregnancy at GHESKIO. Between 2007-2009 and 2013-2016,
the proportion of pregnancies with prior ART exposure increased from 11% to 58% and duration of prior
exposure increased from a median of 15.0 months (IQR: 5.8-40) to 26.1 months (IQR: 12.3-51.9). There
was also an increase in CD4 count at PMTCT entry, from 425 cells/µl (IQR: 289-575) in 2007-2009 to 463
cells/µl (IQR: 309-656) in 2013-2016. At least 28% of the pregnancies were delivered outside of a clinical
setting.
Compared to pregnancies included in the analysis, excluded pregnancies were more likely to have
been the woman’s first at GHESKIO (81% vs 71%) and have had no prior ARV exposure (30% vs 9%).
Blood pressure measurements
The median number of blood pressure measurements during pregnancies was similar over the
three periods, ranging from 5 to 6, and almost all pregnancies had a measurement recorded on the day
of PMTCT entry (96%-98%). Median time between measurements was 4 weeks and most follow-up
measurements were taken within > 2 to 6 weeks after preceding measurement. (Table 2)
In each period, there were relatively fewer measurements early in the pregnancy (blue color) than
later in the pregnancy (red color). In 2007-2009, there was a slightly greater concentration of
measurements around 12-15 weeks before delivery, while in 2010-2016, the greatest concentration was
roughly in weeks 2-8 before delivery. (Figure 2)
Hypertension prevalence and incidence
Overall, applying the two-day hypertension definition, 2.5% of pregnancies were affected by
chronic hypertension and 4.8% - by gestational hypertension. Among pregnancies without hypertension
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at entry, the incidence rate was 11.2 per 100 person-years of follow-up. Among pregnancies with
hypertension at any point, 37.9% reached stage 2. (Table 4)
There was a marked temporal trend in all of the measures. Chronic and gestational hypertension
increased from 1.1% to 3.5% and from 2.3% to 6.9%, respectively, between 2007-2009 and 2013-2016
(p-values 0.003 and <0.001, respectively). Prevalent hypertension increased from 1.3% to 3.8%, while
the incidence rate increased from 5.0 to 16.1 per 100 person-years (p-values 0.005 and <0.001,
respectively).
MAP trajectories and factors associated with higher trajectories
Five MAP trajectories were identified: low-stable (458 or 19.8% of pregnancies, with final estimated
MAP of 72.4), low-increasing (1,037 or 45.0% of pregnancies, with final estimated MAP of 81.9),
moderate-increasing (585 or 25.4% of pregnancies, with final estimated MAP of 93.2), elevatedincreasing (200 or 8.7% of pregnancies, with final estimated MAP of 109.9), and high-increasing (26 or
1.1% of pregnancies, with final estimated MAP of 131.6). (Figure 3) Pregnancies were classified into
trajectory groups with good discrimination; the mean probability of group membership was 0.86 (range
0.85-0.98 across the five trajectory groups).
In multivariable analysis, there was a monotonous trend of increasing odds of higher MAP
trajectory with longer duration of ART exposure prior to PMTCT entry. Pregnancies with > 1 to 3 years or
> 3 years of prior ART exposure had 2.7 times the adjusted odds of higher map trajectory (95% CI: 1.74.3 and 1.6-4.5, respectively) as pregnancies with no prior ART exposure. Older age was also associated
with greater odds of higher MAP trajectory (aOR for age > 40 versus 20-40 years = 2.5, 95% CI: 1.3-4.7),
as were pregnancies which were the women’s first at GHESKIO (aOR first vs second pregnancy = 1.5,
95% CI: 1.02–2.1), and higher weight at entry (aOR for each additional kilogram = 1.03, 95% CI: 1.011.04). (Table 4)
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DISCUSSION
The rates of hypertension in pregnancy have increased in HIV-infected women receiving PMTCT
care in Port-au-Prince. A tenth of pregnancies had an elevated-increasing or high-increasing MAP
trajectory, further suggesting an appreciable risk of hypertension disorders of pregnancy such as preeclampsia among a subset of women receiving PMTCT care. Longer ART exposure was strongly
associated with higher MAP trajectories, pointing to a potential driver of pre-eclampsia risk, as well as
increases in hypertension, in this population. The population under study has high background
prevalence of HIV,2 high blood pressure and hypertension risk factors, such as overweight and obesity,13
highlighting an urgent need to provide hypertension screening and treatment for pregnant women.
Over the study period, at least 2.5% of pregnancies were affected by chronic hypertension and
another 4.8% - by gestational hypertension, which increases the risk of pre-eclampsia. In 2013-2016,
chronic hypertension was identified among 3.5% of pregnancies and gestational hypertension – among
6.9%. The latter estimate is higher than the 5.8% incidence of hypertensive disorders (comprising
gestational hypertension, pre-eclampsia, and eclampsia) among singleton deliveries to women with a
median age of 28 (similar to this study) at four rural referral hospitals across Haiti in 2012-2014.8 The
latter study included complicated pregnancies referred from smaller facilities, and reported 5.2%
stillbirth and maternal death rate, outcomes which were strongly associated with hypertensive disorders
of pregnancy, but were excluded from the current study, decreasing the representation of women in
poor health and/or with high-risk pregnancies. Additionally, this study included patients with as few as 3
months of follow-up and 3 blood pressure measurements, limiting the opportunity to capture and
confirm hypertension using the gold standard two-day definition, though it is not clear how much
follow-up data the hospital-based study accrued. The current study, on the other hand, included
multiple pregnancies, also a risk factor for hypertensive disorders of pregnancy, complicating the
comparison.
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Outside Haiti, a 2002-2009 multicountry study of hypertensive disorders among pregnant HIVpositive women in Brazil, Argentina, Peru, Mexico, Bahamas, and Jamaica, diagnosed 4.8% of pregnant
women with hypertension after 20 weeks of gestation,5 twice as high as the 2.3% of pregnancies with
gestational hypertension in the first period (2007-2009) of this study. However, the multicountry study
only included women’s first pregnancies during the study,5 increasing the representation of primiparous
women who have a greater risk of gestational hypertension. A 2014-2015 study among women with
unknown HIV status and a median age of 24 years in Botswana reported diagnosis of any type of
hypertension by the single-day definition as 22.2%,45 similar to the 23.0% metric in this study’s third
period (2013-2016). Comparisons across studies are complicated, however, by the inconsistent
reporting of sample age distributions.
The estimate of chronic hypertension in the study is lower than the 5.3% hypertension at entry
among ART-naïve GHESKIO patients with CD4 counts between 200 and 350 cells/µl, and with the median
age of 39 years, participating in a 2005-2008 trial of early versus deferred ART initiation.46 In the first
period of this study (2007-2009), among a healthier and younger population with a median age of 28
and a median CD4 count of 425 cells/µl, 1.3% of pregnancies were affected by chronic hypertension.
However, the estimates cannot be compared directly, since the latter is on the pregnancy, rather than
patient level.
Prevalence and incidence of hypertension increased over time, alongside increases in ART exposure
and its duration. There was no evidence of increase in other measured risk factors such as maternal age
or BMI; however, data on the latter were highly incomplete in the early years of the study. Duration of
ART exposure was strongly associated with higher MAP trajectories, a measure previously linked to a
greater risk of pre-eclampsia.10-12 While some studies have reported higher rates of hypertensive
disorders of pregnancy27 or pre-eclampsia specifically33 among HIV-positive women overall or HIVpositive women with ART exposure in particular,5,34 possibly due to immune reconstitution, evidence is
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mixed.22-26,28-32 In the general HIV-positive population, low-magnitude associations between cumulative
exposure to specific ARVs and hypertension onset or blood pressure change on anti-hypertensive
therapy have been reported.47-49 However, this study lacked data to assess ARV exposure in detail.
In addition to ART exposure, advanced maternal age (40 years or older) was associated with greater
odds of a higher MAP trajectory, consistent with prior research on gestational hypertension and preeclampsia among HIV-positive5 and general populations.39,50,51 Although pregnancies to women over 40
years old constituted only 3% of pregnancies in the PMTCT program, the results warrant close attention
to this age group. Pregnancies that were the women’s first in the PMTCT program, a proxy for
primiparity, also had greater odds of a higher MAP trajectory, consistent with documented risk factors
for hypertensive disorders of pregnancy.39,44 Higher MAP trajectories were more likely in pregnancies
with higher weight at entry, consistent with evidence on pre-pregnancy BMI and pre-eclampsia.52
The observed increasing trends in hypertension may also be driven in part by an apparent slight
increase over time in the availability of blood pressure measurements recorded later in the pregnancy.
However, the most recent estimates are likely to be more accurate, as estimates for the earlier periods,
relying more heavily on measurements earlier in the course of pregnancy, may have been less likely to
capture cases of incident, particularly gestational, hypertension. In rural Haiti, two analyses a decade
apart did not indicate an increase in the prevalence of eclampsia or pre-eclampsia among women
delivering in a hospital;6,7 however, no other trend data from Haiti are available for comparison.
In addition to monitoring for sustained elevated blood pressure, pre-eclampsia screening typically
relies on relatively low-cost methods such as urine dipstick test for proteinuria,3 despite its potentially
low accuracy for detection of proteinuria during pregnancy.44,53 Proteinuria is also not always present in
patients with pre-eclampsia.44 In its absence, or when testing is not available, thrombocytopenia, renal
insufficiency, impaired liver function, pulmonary edema, or visual or cerebral symptoms can also
confirm the diagnosis of pre-eclampsia;44 however, screening is also not readily available in resource-
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constrained settings. Properly measured blood pressure remains the key diagnostic tool for
hypertensive disorders of pregnancy, stressing the importance of consistent measurement and
recording of blood pressure in medical records, even as low-cost tests for proteinuria are developed for
low-income settings.54,55 Mobile health (mHealth) approaches are also increasingly examined as tools for
patient and provider education, and screening for and management of hypertensive disorders of
pregnancy in low-resource settings,56 but may face challenges in integration into health systems and
limited internet connectivity.
In addition to pre-eclampsia management, which can include antihypertensive treatment and
administration of magnesium sulfate,3,44 attention to the background prevalence of chronic
hypertension is warranted. As women increasingly enter PMTCT with a history of HIV care, many cases
of pre-existing hypertension can be detected and managed prior to conception and PMTCT entry. Since
there are no hypertension screening or treatment guidelines specific to HIV-positive populations,15
general recommendations apply.57,58 Ambulatory monitoring of blood pressure can also be considered
for HIV-positive individuals,59 as masked hypertension and abnormalities in diurnal blood pressure
patterns have been documented in this population.60,61 Resource constraints, however, may make
ambulatory monitoring infeasible in low-income countries.
Finally, deliveries outside the clinical setting, even among women who had accessed several
months of antenatal care, highlight the importance of addressing potential risks to the woman and fetus
prior to or early in the pregnancy, given limited availability of specialized medical help at the time of
many deliveries.
The major strength of the study was its use of data spanning a 10-year period, enabling
characterization of hypertension trends over time. Limitations include blood pressure measurements
mostly recorded in cmHg, which did not affect the application of hypertension definitions, but
constituted imprecise data for trajectory modeling. Several factors may have led to underestimation of

77

hypertension: the lack of prescription data for hypertension treatment, inclusion of pregnancies with as
few as 3 blood pressure measurements available, and the requirement of at least 3 months PMTCT
follow-up, which may have excluded women with diagnosed pre-eclampsia and potentially earlier,
provider-induced deliveries.62,63 Because of the lack of laboratory data, it was not possible to identify
likely cases of pre-eclampsia. There were also no data available for several hypertension risk factors,
such as pre-pregnancy BMI, diet, smoking, diabetes, chronic kidney disease, family history, exposure to
stress, and parity. Secular trends in other risk factors, such as BMI or diet, could be contributing to the
observed increases in hypertension over time. Some characteristics of pregnant women, such as
education or income, were only recorded for the first pregnancy at GHESKIO and could have changed
before subsequent pregnancies. Because of incomplete data on pregnancy outcomes and the inclusion
of “unknown” outcomes in the analysis, some pregnancies which ended in stillbirth may have been
included, though less likely abortions, due to the inclusion criterion requiring at least 3 months of
PMTCT follow-up.
Importantly, because of the same inclusion criterion, findings cannot be generalized to pregnancies
not supported by PMTCT and/or antenatal services, or which received such care only at late stages. Such
pregnancies, likely among women with less access to healthcare and possibly very low socioeconomic
status, may be at even higher risk of poor outcomes, including hypertension.
CONCLUSION
This study documents a substantial and increasing prevalence and incidence of chronic and
gestational hypertension in a large PMTCT program in Port-au-Prince, Haiti. The findings point to a need
for treatment prior to PMTCT entry as well as during PMTCT follow-up, to minimize the risk of pregnancy
complications and negative outcomes for the women and fetuses, and to protect long-term health of
the women. Since the population under study is largely very low-income, with limited access to chronic
disease care, and many deliveries continue to occur outside of a clinical setting, the period of PMTCT
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follow-up represents a potentially rare opportunity to diagnose and initiate management of chronic and
gestational hypertension alike.
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Figure 1. Cohort selection diagram, pregnancies in a PMTCT program, Port-au-Prince, Haiti, 2007-2016.

BP = blood pressure

Figure 2. Distribution of blood pressure measurements over time, by period, among pregnancies in a
PMTCT program, Port-au-Prince, Haiti, 2007-2016.
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Figure 3. Trajectories of mean arterial blood pressure (MAP) among 2,306 pregnancies in a PMTCT
program, Port-au-Prince, Haiti, 2007-2016.
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Table 1. Characteristics of 4,123 pregnancies (2,306 included, 1,817 excluded) in a PMTCT program, Port-au-Prince, Haiti, 2007-2016.
Included pregnancies, by period of entry
Characteristic

All excluded:
N (%) or
Median (IQR)

All included:
N (%) or
Median (IQR)

2007-2009:
N (%) or
Median (IQR)

2010-2012:
N (%) or
Median (IQR)

2013-2016:
N (%) or
Median (IQR)

N pregnancies

1,817

2,306

617

730

959

N women with pregnancy in period

1,677

1,965

596

703

906

2007-2009

581 (32%)

617 (27%)

2010-2012

632 (35%)

730 (32%)

2013-2016

604 (33%)

959 (42%)

Period of entry

Sociodemographic characteristics of the pregnant woman*
Age at PMTCT entry (years)
Age category

28 (23,33 )

29 (25,34 )

28 (24,33 )

29 (25,34 )

29 (24,34 )

< 20 years

182 (10%)

124 (5%)

42 (7%)

28 (4%)

54 (6%)

20 – 40 years

1585 (87%)

2124 (92%)

564 (91%)

680 (93%)

880 (92%)

50 (3%)

58 (3%)

11 (2%)

22 (3%)

25 (3%)

None

301 (17%)

323 (14%)

100 (16%)

100 (14%)

123 (13%)

Primary

763 (42%)

894 (39%)

242 (39%)

292 (40%)

360 (38%)

Secondary
University or professional
Unknown

722 (40%)
21 (1%)
10 (1%)

1037 (45%)
34 (1%)
18 (1%)

260 (42%)
11 (2%)
4 (1%)

327 (45%)
10 (1%)
1 (0%)

450 (47%)
13 (1%)
13 (1%)

None

1055 (58%)

1259 (55%)

335 (54%)

371 (51%)

553 (58%)

≤ 5,000 goudes**

338 (19%)

465 (20%)

107 (17%)

133 (18%)

225 (23%)

> 5,000 goudes**

408 (22%)

565 (25%)

173 (28%)

223 (31%)

169 (18%)

16 (1%)

17 (1%)

2 (0%)

3 (0%)

12 (1%)

> 40 years
Education level

Woman's annual income

Unknown
Marital status

Residence area

Divorced or widowed

62 (3%)

69 (3%)

17 (3%)

14 (2%)

38 (4%)

In a relationship

1105 (61%)

1387 (60%)

402 (65%)

465 (64%)

520 (54%)

Single

637 (35%)

838 (36%)

196 (32%)

250 (34%)

392 (41%)

Unknown

13 (1%)

12 (1%)

2 (0%)

1 (0%)

9 (1%)

Carrefour

388 (21%)

552 (24%)

113 (18%)

182 (25%)

257 (27%)

Delmas

213 (12%)

267 (12%)

72 (12%)

93 (13%)

102 (11%)

17 (1%)

8 (0%)

3 (0%)

2 (0%)

3 (0%)

Plaine

168 (9%)

248 (11%)

79 (13%)

73 (10%)

96 (10%)

Port-Au-Prince

748 (41%)

933 (40%)

275 (45%)

293 (40%)

365 (38%)

Other or unknown

85

Province (outside PAP)

238 (13%)

235 (10%)

51 (8%)

65 (9%)

119 (12%)

45 (2%)

63 (3%)

24 (4%)

22 (3%)

17 (2%)

Yes

868 (48%)

1145 (50%)

282 (46%)

361 (49%)

502 (52%)

No

600 (33%)

796 (35%)

255 (41%)

261 (36%)

280 (29%)

Unknown or outside PAP

349 (19%)

365 (16%)

80 (13%)

108 (15%)

177 (18%)

Pétion-Ville
Neighborhood with a high
slum concentration

Characteristics of the pregnancy and woman's clinical status
Multiple pregnancy

Yes

29 (2%)

57 (2%)

11 (2%)

16 (2%)

30 (3%)

Sequence at GHESKIO

1

1470 (81%)

1634 (71%)

494 (80%)

516 (71%)

624 (65%)

2

260 (14%)

493 (21%)

104 (17%)

158 (22%)

231 (24%)

3+

87 (5%)

179 (8%)

19 (3%)

56 (8%)

104 (11%)

Gestational age at PMTCT entry (weeks)

25 (14,31)

15 (10,20)

15 (10,21)

15 (10,20)

14 (10,20)

Time from HIV diagnosis to
PMTCT entry available

1208 (66%)

1887 (82%)

521 (84%)

593 (81%)

773 (81%)

Time from HIV diagnosis to PMTCT entry (months)

20 (0.6,48)

30 (8,62)

13 (0.2,44)

34 (11,60)

39 (15,77)

ARV exposure respective to
PMTCT entry

None ever until delivery

546 (30%)

209 (9%)

106 (17%)

87 (12%)

16 (2%)

ARV mono- or bi- at or
after entry

357 (20%)

472 (20%)

382 (62%)

90 (12%)

0 (0%)

ART initiated at entry

542 (30%)

793 (34%)

62 (10%)

340 (47%)

391 (41%)

ART for up to a year
before entry

129 (7%)

252 (11%)

30 (5%)

88 (12%)

134 (14%)

ART for > 1-3 years before
entry

147 (8%)

316 (14%)

17 (3%)

88 (12%)

211 (22%)

96 (5%)

264 (11%)

20 (3%)

37 (5%)

207 (22%)

19 (8,37)

23 (9,44)

15 (6,40)

17 (6,31)

26 (12,52)

465 (304,642)

444 (306,604)

425 (289,575)

439 (308,588)

463 (309,656)

Yes

ART for > 3 years before
entry
If received ART prior to PMTCT entry, duration of prior
ART (months)
CD4 count at PMTCT entry (+/- 30 days), cells/µl
CD4 count category

WHO stage at PMTCT entry

≤ 200 cells/μl

146 (8%)

171 (7%)

53 (9%)

52 (7%)

66 (7%)

201-350 cells/μl

258 (14%)

358 (16%)

108 (18%)

132 (18%)

118 (12%)

351-500 cells/μl

286 (16%)

414 (18%)

119 (19%)

146 (20%)

149 (16%)

> 500 cells/μl

564 (31%)

613 (27%)

156 (25%)

207 (28%)

250 (26%)

Unknown

563 (31%)

750 (33%)

181 (29%)

193 (26%)

376 (39%)

1

1436 (79%)

1643 (71%)

475 (77%)

459 (63%)

709 (74%)
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BMI at PMTCT entry (+/- 30
days) available

2

174 (10%)

272 (12%)

74 (12%)

107 (15%)

91 (9%)

3

109 (6%)

207 (9%)

56 (9%)

68 (9%)

83 (9%)

4

98 (5%)

184 (8%)

12 (2%)

96 (13%)

76 (8%)

831 (46%)

1297 (56%)

115 (19%)

241 (33%)

941 (98%)

22.5 (20.4,25.3)

22.2 (20.1,24.8)

22.9 (20.5,25.5)

22 (20.2,24.2)

22.1 (20,24.8)

Non-clinical setting (e.g.
home, street)

581 (32%)

656 (28%)

166 (27%)

203 (28%)

287 (30%)

Clinical setting

690 (38%)

1393 (60%)

396 (64%)

456 (62%)

541 (56%)

Unknown

546 (30%)

257 (11%)

55 (9%)

71 (10%)

131 (14%)

Yes

BMI at PMTCT entry (+/- 30 days)
Place of delivery

* These variables (except age) were only collected at the time of first PMTCT entry
** As of July 2019, 5,000 goudes equals 53 USD
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Table 2. Characteristics of blood pressure measurements among 2,306 pregnancies in a PMTCT
program, Port-au-Prince, Haiti, 2007-2016.
Overall
(N = 2,306
pregnancies)

2007-2009
(N = 617
pregnancies)

2010-2012
(N = 730
pregnancies)

2013-2016
(N = 959
pregnancies)

6 (4, 7)

6 (4, 7)

5 (4, 7)

6 (5, 8)

2,243 (97%)

593 (96%)

719 (98%)

931 (97%)

63 (3%)

24 (4%)

11 (2%)

28 (3%)

4.1 (3.0, 4.5)
N = 11,490
measurements
3,081 (27%)

4.0 (2.6, 4.6)
N = 2,991
measurements
951 (32%)

4.1 (3.0, 4.5)
N = 3,438
measurements
868 (25%)

4.1 (3.1, 4.4)
N = 5,061
measurements
1,262 (25%)

Within > 2 - ≤ 4 weeks of prior

2,968 (26%)

695 (23%)

890 (26%)

1,383 (27%)

Within > 4 - ≤ 6 weeks of prior

4,265 (37%)

945 (32%)

1,284 (37%)

2,036 (40%)

Within > 6 weeks of prior

1,176 (10%)

400 (13%)

396 (12%)

380 (7%)

Number of measurements during pregnancy
(on distinct days): Median (IQR)
Time from PMTCT entry to first measurement
Same day
Not same day
Time between measurements (weeks)
Median (IQR) of pregnancy-level medians
Among measurements that were not first
measurements
Within ≤ 2 weeks of prior

Table 3. Blood pressure and hypertension during PMTCT follow-up of 2,306 pregnancies, by period,
Port-au-Prince, Haiti, 2007-2016.
Overall

2007-2009

2010-2012

2013-2016

Median SBP** (IQR)

105 (95-110)

95 (90-105)

105 (95-115)

105 (95-115)

Median DBP** (IQR)

65 (65-75)

65 (55-65)

65 (65-75)

75 (65-80)

p-value*

Using the two-day hypertension definition
Hypertension type***
Chronic

2.5% (1.9 - 3.2%)

1.1% (0.5 - 2.3%)

2.3% (1.4 - 3.7%)

3.5% (2.5 - 4.9%)

0.003

Gestational

4.8% (3.9 - 5.7%)

2.3% (1.2 - 3.8%)

4.1% (2.8 - 5.8%)

6.9% (5.4 - 8.7%)

<0.001

Stage 2 hypertension at any two consecutive measurements among those with hypertension***
Yes

37.9% (30.5 - 45.6%)

52.4% (29.8 - 74.3%)

38.3% (24.5 - 53.6%)

34.7% (25.5 - 44.8%)

1.3% (0.6 - 2.6%)

2.2% (1.3 - 3.6%)

3.8% (2.7 - 5.2%)

0.005

16.1 (12.6 - 20.0)

<0.001

Prevalence at PMTCT entry
Hypertension

2.6% (2.0 - 3.3%)

Incidence rate among those free of hypertension at PMTCT entry, per 100 person-years
Hypertension

11.2 (9.3 - 13.4)

5.0 (2.7 - 8.4)

10.0 (6.9 - 14.0)

Using the single-day hypertension definition
Hypertension type***
Chronic
Gestational

5.6% (4.7 - 6.6%)

2.9% (1.7 - 4.6%)

4.1% (2.8 - 5.8%)

8.3% (6.7 - 10.3%)

11.4% (10.1 - 12.8%)

6.3% (4.5 - 8.5%)

11.4% (9.2 - 13.9%)

14.7% (12.5 - 17.1%)

Stage 2 hypertension at any single measurement among those with hypertension***
Yes

44.3% (39.3 - 49.3%)

50.9% (37.3 - 64.4%)

43.9% (34.6 - 53.5%)

42.8% (36.2 - 49.6%)

3.1% (1.9 - 4.8%)

3.7% (2.5 - 5.4%)

8.1% (6.6 - 10.0%)

Prevalence at PMTCT entry
Hypertension

5.4% (4.5 - 6.4%)

Incidence rate among those free of hypertension at PMTCT entry, per 100 person-years
Hypertension

28.9 (26.1 - 31.9)

14.9 (11.1 - 19.9)

29.1 (24.2 - 34.5)

38.2 (33.4 - 43.2)

*P-values are model-based (logistic for prevalence, Cox for incidence) and account for clustering of pregnancies within women
**Median SBP and DBP values are medians of pregnancy-level medians
***Hypertension type and stage combines prevalent and incident hypertension cases
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Table 4. Factors associated with higher MAP trajectories among 2,306 pregnancies in a PMTCT
program, Port-au-Prince, Haiti, 2007-2016.
Variable
OR (95% CI)
Period
2007-2009
ref
2010-2012
2.3 (1.4 - 3.5)
2013-2016
3.2 (2.1 - 4.9)
Woman's sociodemographic characteristics
Age at PMTCT entry
< 20 years
0.47 (0.20 - 1.1)
20 – 40 years
ref
> 40 years
2.8 (1.5 - 5.4)
Education level
None
ref
Primary
0.69 (0.44 - 1.1)
Secondary, university, or professional
0.94 (0.61 - 1.4)
Clinical HIV & pregnancy characteristics
CD4 count at PMTCT entry
≤ 200 cells/μl
1.1 (0.65 - 1.9)
201-350 cells/μl
0.80 (0.51 - 1.3)
351-500 cells/μl
0.92 (0.60 - 1.4)
> 500 cells/μl
ref
Unknown
0.85 (0.60 - 1.2)
WHO stage at PMTCT entry
1
ref
2
0.86 (054 - 1.3)
3
0.94 (0.55 - 1.6)
4
1.4 (0.88 - 2.2)
ART status respective to PMTCT entry
None ever until delivery*
ref
ART initiated at PMTCT entry
1.7 (1.1 - 2.6)
ART for up to a year before PMTCT entry
2.0 (1.2 - 2.2)
ART for > 1-3 years before PMTCT entry
2.6 (1.6 - 4.0)
ART for > 3 years before PMTCT entry
2.6 (1.6 - 4.2)
Pregnancy sequence at GHESKIO
1
1.2 (0.83 - 1.6)
2
ref
3+
1.6 (0.92-2.7)
Weight at PMTCT entry
One kg increase
1.03 (1.02-1.04)
*Includes ARV mono- and bi- exposure after PMTCT entry

p-value

aOR (95% CI)

p-value

0.58 (0.25 - 1.4)
ref
2.5 (1.3 - 4.7)

0.037

<0.001

ref
1.7 (1.1 - 2.5)
1.9 (1.1 - 3.1)
2.7 (1.7 - 4.3)
2.7 (1.6 - 4.5)

0.002

0.280

1.5 (1.02 - 2.1)
ref
1.5 (0.80 - 2.6)

0.067

<0.001

1.03 (1.01 - 1.04)

<0.001

<0.001

0.004

0.112

0.756

0.501
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Supplemental Table 1. Prevention of mother-to-child-transmission (PMTCT) national guidelines in
Haiti, 2007 - 2016.
Period

Maternal ART and PMTCT guidelines

2007 - 2009

ART:
- Eligibility: CD4 count ≤ 250 cells/µl
- Regimen: AZT+3TC+NVP
PMTCT:
- Eligibility: CD4 count > 250 cells/µl
- Regimen:
- If woman presented at ≤28 weeks: AZT at 28 weeks gestation plus AZT + 3TC during delivery
and one week post-partum
- If woman presented at > 28 but ≤ 36 weeks: AZT + 3TC at 36 weeks gestation plus AZT increase
during labor, plus AZT + 3TC one week post-partum
- If woman presented in labor: AZT + 3TC for one week or AZT during labor or NVP single dose

2010 - September
2012

October 2012 2016

ART:
- Eligibility: CD4 count ≤ 350 cells/µl
- Regimen: AZT + 3TC + NVP/EFZ, AZT + 3TC +LPV-r, or TDF + 3TC + NVP/EFZ
PMTCT Option B:
- Eligibility: CD4 count > 350 cells/µl, unknown or WHO stage I/II
- Regimen: ART as defined above at 14 weeks gestation through the end of breastfeeding
ART:
- Eligibility: CD4 count ≤ 500 cells/µl
- Regimen: TDF + 3TC + NVP/EFZ
PMTCT Option B+:
- Eligibility: Lifelong ART for all pregnant and breastfeeding women regardless of CD4 count
Note: In July 2016 Haiti expanded treatment eligibility to all patients.
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CHAPTER 5. DISCUSSION
INTRODUCTION
This study assessed the burden of hypertension and unmet healthcare needs in a resource-poor,
urban setting with a high concentration of slum communities. By examining the questions of interest
within a random slum community sample (the first such published analysis in Haiti, to my knowledge), a
cohort of clinic patients newly initiating ART, and a cohort of pregnant women with varying levels of
exposure to ART, this work enhances the understanding of epidemiology of hypertension in a setting
with a substantial background prevalence of HIV, as well as among PLWH specifically. The final chapter
summarizes and synthesizes findings from each of the three subpopulations, and outlines programmatic
implications and future research directions.
SUMMARY OF RESULTS
Chapter 2 used data from a 2016 cross-sectional, population-representative survey of four Port-auPrince slum neighborhoods to examine the prevalence of hypertension, associated factors, and the
hypertension care continuum. The adult population was young (median age 28 years) and mobile: four
in ten residents had moved there within the prior three years, and most migrants came from another
location in metropolitan Port-au-Prince area. Risk factors for hypertension were common: overweight,
obesity, or central obesity affected more than half of women, and diets consisted largely of fried foods,
with infrequent consumption of fresh fruits and vegetables. There was an unmet need for healthcare
services, as over a quarter of participants had not received needed care in the preceding six months.
Using a single-day hypertension definition, a fifth of adults were classified as having hypertension,
and another quarter – pre-hypertension, with substantial prevalence across the age spectrum.
Prevalence was particularly high (29%) among persons who reported not receiving needed medical care
in the six months prior. More women than men reported having ever had their blood pressure
measured before. Four out of ten persons with hypertension on the day of the survey had been
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previously told by a clinician that they had the condition, but fewer than one in ten were receiving
treatment. Among men, having moved to the community in the preceding three years was
independently associated with higher odds of hypertension, while among women failure to receive
needed healthcare, overweight, and obesity were linked to the condition. Irrespective of sex, increasing
age and prevalence of hypertension in immediate surroundings were also associated with higher
individual odds of hypertension.
Chapter 3 assessed the burden of hypertension using longitudinal medical records data among
newly diagnosed with HIV and initiating ART patients between 2013 and 2017. The gold-standard twoday definition of hypertension was used. In this fairly young sample (median age 37 years), with
relatively low prevalence of overweight and obesity, 11.6% of patients had hypertension at study
enrollment and among those initially hypertension-free, 18.5% had developed hypertension within the
first 18 months of HIV care and treatment. Recognized risk factors, overweight or obesity at baseline
and older age, were associated with increased risk of incident hypertension, as was low CD4 count (≤100
cells/ml) at enrollment.
Among patients with prevalent or incident hypertension, 44% of patients had hypertension on half
or more of the subsequent measurements over a median of 24 months of follow-up. Patients with initial
stage 1 hypertension and younger patients were less likely to maintain hypertensive status during
follow-up. At the same time, low (SBP <90 mmHg) but not high (SPB ≥140) blood pressure at enrollment
was associated with increased risk of mortality in the first year of follow-up: controlling for age and sex,
patients with initial SBP <90 mmHg had 3.7 times the risk of death (95% CI: 1.1-12.6) as patients with
initial SBP between 90-139 mmHg.
In chapter 4, longitudinal medical record data were used to examine trends in chronic and
gestational hypertension among pregnant women with HIV in a PMTCT program over the period
spanning 2007-2016, using the two-day definition of hypertension. Similar to the two preceding
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chapters, the population was young, with a median age at PMTCT entry of 29 years. Both types of
hypertension increased over the time under study, with more than one in ten pregnancies affected by
chronic or gestational hypertension in the most recent period (2013-2016); three times the estimate for
2007-2010. In addition to recognized risk factors such as older maternal age and a proxy for primiparity,
increased duration of prior ART exposure was strongly associated with higher MAP trajectories, a
possible risk factor for pre-eclampsia. Pregnancies among women with more than a year of prior ART
had almost three times the adjusted odds of a higher MAP trajectory as pregnancies without prior ART
exposure. Approximately a third of deliveries took place in a non-clinical setting.
STRENGTHS
This work provides a multifaceted examination of the hypertension landscape across three distinct
populations, including a difficult to systematically study slum setting, in the context of growing CVD and
NCD burden, and against a backdrop of substantial HIV prevalence. As urbanization across many LMICs
continues, and populations increasingly reside in disadvantaged slum settings, it is essential to better
understand their needs and adapt healthcare services for the intersection of communicable and noncommunicable conditions.
To help inform service adaptations and the potential need for further study, this study provides a
wealth of high-quality data: population-representative, cross-sectional data from four slum
communities, and longitudinal data over a period of up to 10 years among PLWH receiving free medical
care at a local clinic. Findings from the community survey offer a rare, comprehensive characterization
of hypertension in this setting, as well as living conditions and healthcare needs of slum residents, which
have previously been poorly described in the region. Clinic-based data provide insights into
hypertension trends over time (and possible growing future burden), as well as the trajectory of the
condition within individuals in a resource-poor setting with limited access to treatment. Moreover, the
use of latent class models to identify blood pressure trajectories in pregnancy, and multinomial ordinal
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regression to examine associations with ART history, is a novel approach that contributes to the mixed
body of evidence on cumulative ART exposure and hypertension.
LIMITATIONS
The main limitations of this work lie in the absence of relevant data elements. The cross-sectional
design of the community study, albeit common in field-based surveys, required the use of a single-day
hypertension definition, which overestimated its prevalence. Across all three aims, data on important
hypertension risk factors were not available, for example physical activity, family history, or
comorbidities. In clinic-based data, although hypertension treatment is believed to have been rare (as it
was not routinely accessible at the facility), no information on receipt of anti-hypertensive treatment
was available. This likely lead to a slight underestimate of hypertension prevalence and incidence, and
made it impossible to distinguish between treated and untreated hypertension. Lack of urine protein
test data for pregnant women prevented the application of a common, albeit imperfect, definition of
pre-eclampsia, the risk of which was instead only approximated by the levels of gestational hypertension
alone. Lack of data on exact ART regimens received over time, treatment gaps, and longitudinal CD4
counts, precluded the use of time-varying covariates in models of incident hypertension or its more
direct assessment in the context of immune reconstitution. Recording of many clinic-based blood
pressure measurements in cmHg rather than mmHg limited their utility as a continuous measure.
Finally, in contrast to the population-representative community survey with high completion rates,
analyses of clinic data relied on highly self-selected samples: pregnant women with at least 3 months of
PMTCT follow-up, and PLWH who consented to participate in a clinical trial and who did not
immediately drop out. Consequently, findings from those analyses are likely less applicable to PLWH
who are not engaged in care, and who may have even more complex challenges and needs.
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PROGRAMMATIC IMPLICATIONS AND FUTURE RESEARCH DIRECTIONS
The findings highlight the potential for continued growth in the hypertension and NCD burden in
Haiti, as well as unmet need for prevention, screening, and quality treatment services. In addition to
secular trends in these conditions, the increase in cumulative exposure to ART might further fuel the rise
in hypertension and CVD in settings with high HIV prevalence such as Haiti. Interventions and further
research across the hypertension care continuum are needed to strengthen and expand services
increasingly needed by the affected populations.
Screening in community and medical facility settings: This study demonstrated the feasibility of
screening and monitoring blood pressure in community- and facility-based populations in a low-resource
setting. However, the quality of screening is of great importance, to enable appropriate targeting of
prevention and treatment. This study’s finding of inconsistent hypertension trajectories among patients
receiving HIV care in likely absence of hypertension treatment highlights the need to accurately measure
and record blood pressure. Measurement error, regression to the mean, and white-coat1 and masked
hypertension2,3 may all complicate the identification of true cases of hypertension, in particular on the
lower part of the age spectrum. Ambulatory monitoring should be considered for patients whose blood
pressure levels do not clearly or consistently fall in the hypertensive range, to improve specificity of
screening. Ambulatory monitoring to identify masked cases (improving sensitivity of screening) would
not be cost-effective if applied to the entire patient population. However, it can target patients more
likely to have masked hypertension, identified in the United States as persons with pre-hypertension or
diabetes, men, and persons 45 years of age or older.2 Research comparing blood pressure measures
collected in healthcare facilities and by community health workers to those from ambulatory
monitoring, can improve the understanding of white coat and masked hypertension in low-resource
settings, allowing refinement of screening algorithms to best serve local populations.
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Screening during and prior to pregnancy: Low-cost, accurate tools for testing of proteinuria and
kidney function by non-specialized personnel can help inform appropriate hypertension treatment
among PLWH,4 and better identify pre-eclampsia among pregnant women specifically.5,6 Because of
limited availability of specialized birthing assistance, facilities, and post-natal care, as well as some
women’s preferences regarding childbirth, many births continue to take place outside of a clinical
setting and may lack subsequent clinical follow-up. This reality makes it imperative not only that diligent
assessments of hypertensive disorders of pregnancy be performed during PMTCT follow-up, but also
that routine HIV care appointments be leveraged to diagnose and manage pre-existing hypertension
prior to possible pregnancy.
Integrated HIV and NCD care: UNAIDS recommends that vertical HIV care programs, adept at
providing continuous care for an initially minimally symptomatic condition that requires patient selfmanagement, an important similarity between HIV and NCDs, leverage their tools and approaches to
scale up NCD services.7 Integration of hypertension services within existing HIV and tuberculosis
programs has also been identified by the Pan-African Society of Cardiology as a key action item for
improving cardiovascular health on the continent.8 With fragmented LMIC healthcare systems that are
poorly equipped or resourced to provide care for patients with multimorbidity,9 HIV programs present
an important opportunity to efficiently introduce and scale up NCD services while minimizing the costs
needed to do so,10 both in general HIV-positive populations and in PMTCT settings specifically. To date,
however, substantial gaps in readiness to provide NCD care have been documented in HIV care
programs10,11 and attempts at integrating services within different levels of healthcare systems have had
mixed success.12,13 Staffing shortages, inadequate equipment, drug stock-outs, and difficulty obtaining
buy-in from overburdened staff were some of the reported challenges.10,13 At GHESKIO specifically, a
recent pilot of integrated HIV and hypertension care reported high retention and moderate
hypertension control over a six-month period.4 HIV care clinicians were trained to incorporate

96

hypertension screening and management into routine HIV visits, limiting the need for additional staffing
and not requiring patients to return to the clinic more than they used to for HIV care alone. The program
relied on low-cost point-of-care proteinuria screening as marker for kidney function, part of the
treatment algorithm, and utilized drugs from the WHO list of essential medicines, in order to maximize
affordability and accessibility. Financial considerations may constitute a major barrier to extending NCD
care in the absence of a large-scale vertical funding source similar to PEPFAR for HIV.
Locally appropriate, multimodal, differentiated care models: For the programs to be successfully
adopted and sustainable, it is critical that they be locally owned and contextually appropriate.7,11 In the
context of Port-au-Prince, and many other rapidly urbanizing LMIC settings, largely intraurban migration
and population movement patterns are an important consideration. As documented in this study’s
community survey, many residents are recent migrants and many spend prolonged periods of time away
from their current home. In order to facilitate engagement and retention in hypertension care,
community- and HIV care-based programs alike must accommodate the needs of recent migrants, who
may have limited support networks and be in greater need of resources, and of persons with physical
and logistical barriers to attending appointments. Mobile health (mHealth) approaches, increasingly
studied for hypertension14-17 and hypertensive disorders of pregnancy18 in LMICs, but to date lacking a
strong evidence base,19 should be rigorously evaluated using randomized study designs as possible tools
to improve engagement in care and to facilitate self-management. As integrated HIV and NCD care is
scaled up, research should also assess the impact of differentiated HIV service delivery models, including
decreased frequency of clinic visits20,21 and community distribution of medications, on continuity of
hypertension screening and management. Rigorous assessments of care models for patients with
multimorbidity, including the aging HIV-positive population, will also be critical.
Network effects in hypertension prevention and management: It is also important to investigate in
greater depth how hypertension and other CVD risk factors cluster in dense, rapidly urbanizing and slum
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areas, as well as the ways in which community-level or network effects could be leveraged for
prevention, screening and management of hypertension and other NCDs. Despite the lack of direct NCD
transmission, patients’ families and close networks likely share genetic, dietary, household, and
environmental hypertension risk factors. Not unlike family-based HIV testing and counseling, by
incorporating networks into hypertension prevention, screening, and treatment, programs could
facilitate engagement in care of the index patient and could help effectively identify further cases by
targeting groups with increased pre-test probability of the condition. Such efforts in resourceconstrained and slum settings can be largely driven by community health workers.22,23
Pathogenesis and prediction of hypertension among PLWH: Prospective research into associations
between inflammatory, immunologic, and metabolic markers, and longitudinal blood pressure
trajectories, continues to be needed to elucidate factors that precede and may predict development of
hypertension among PLWH, including chronic inflammation, immune reconstitution, and
lipodystrophy.24,25 As many of these markers are not routinely collected in primary HIV care settings in
LMICs, lab capacity remains an important consideration in development of predictive measures, as is the
case with CVD risk scores more broadly.26 Caution is warranted as HIV programs decrease the frequency
of patient monitoring and CD4 testing in particular, as routine service delivery data may become less
available and usable for characterizing such factors on the individual and population levels.
Low blood pressure among PLWH: Among patients with low blood pressure, it is important to
better understand the interrelation of HIV disease stage, concomitant infections, and other factors that
may be placing these individuals at increased risk of death,27 in order to inform optimal interventions. In
low-resource primary care settings where access to specialized care may be limited, timely identification
of patients in need of immediate and/or more advanced life-saving services is critical.
In all, there was a high burden of hypertension and related risk factors among slum community
residents and PLWH enrolled in a large Port-au-Prince HIV care program. Hypertension, an easily
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measured and major modifiable risk factor for CVD, demands particular attention in Haiti, which has the
world’s highest CVD burden attributable to HIV outside of sub-Saharan Africa, and where secular trends
and longer cumulative HIV and ART exposure among surviving patients may be jointly driving CVD
burden. Across the subgroups studied, individuals showed interest and willingness to engage in medical
care. Facility- and community-based programs have an opportunity to meaningfully improve individual
and population health through expanding existing HIV services to encompass hypertension and NCD
care, and through leveraging community health workers to reach families and networks in need of
prevention, screening, and management services. As programs are scaled up, they must be further
strengthened to care for patients with multimorbidity, both among aging PLWH and among HIVnegative persons facing NCD risk factors associated with dynamic lifestyle and socioeconomic changes
characteristic of the epidemiological transition in urban LMIC settings.
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APPENDIX TO CHAPTER 2: SURVEY DESIGN DETAILS
SURVEY DESIGN
The study was a cross-sectional survey of randomly selected households and individuals living in the
four adjacent slum neighborhoods. To create a sampling frame, each of the communities was divided
into blocks used previously in GHESKIO’s community work, and based on roads and canals cutting
through the area. The blocks were of various sizes and contained different numbers of residential
structures within their borders. Most blocks had an estimated population count based on data gathered
during community-based tuberculosis screening activities. For blocks in Martissant Littoral that did not
have a population count, the block population estimate was based on the average number of people per
structure in the remaining blocks. Data on the number of structures in each block came from
OpenStreetMaps1 and manual review of high resolution 2016 images from the DigitalGlobe Foundation.2
Cluster area random sampling was used to randomly select 111 geospatial waypoints across the
four communities. Each block was assigned a number of waypoints proportional to the estimated
population of that block. ArcGIS was used to randomly generate the waypoints within each block,
excluding commercial buildings and empty spaces. Waypoints were matched to a global positioning
system (GPS) location using a handheld GPS navigation device.
HOUSEHOLD AND INDIVIDUAL SURVEY SAMPLE
Upon locating each waypoint, the fieldworkers followed a protocol to identify the closest five
consecutive households. Households were defined as a person or persons, related or unrelated, who live
together in a residential structure, make common provisions for food, and regularly take their food from
the same pot; similar to the Demographic and Health Survey definitions.3 Up to three attempts were
made to interview eligible household members, who had to be ≥ 18 years old and have slept in the
household at least once in the past 2 nights. Fieldworkers informed adult household members about
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survey goals, content, risks, and voluntary nature of participation. Verbal consent was collected from up
to three eligible household members, who would jointly complete the survey with the interviewer.
At the end of the survey, 2 eligible adult household members were randomly selected from the
household roster to participate in an additional individual survey. In households with two or fewer adult
residents, these residents were invited to participate without random selection. Up to three attempts
were made to interview selected individuals, and a new verbal consent was obtained from participants
for the individual survey after study goals, content, risks, and voluntary nature were discussed.
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